$PVOTF Extracts Maximum Benefit from Cannabis Portfolio

April 6, 2018

• Forecasts predict $55.8 billion valuation for medical cannabis market by 2025
• Pivot Pharmaceuticals building portfolio of diverse tech for improving bioavailability of cannabinoid therapies
• Company’s leadership team builds on decades of experience in pharmaceutical arena

For nutrition-conscious consumers, scanning food product labels is a requisite part of any trip to the grocery store, but a recent study by the U.S. Department of Agriculture’s Agricultural Research Service (http://cnw.fm/i21Ex) found that the old maxim ‘what you see isn’t always what you get’ holds true when it comes to certain foods like nuts. Even though pistachios, for example, may have 161.9 calories per ounce, only 153.8 calories are utilized by the human body. The remaining five percent of those calories are given a pass by the body and not taken up, according to the research. Such information fuels the concept of bioavailability, or determining the portion of total nutrients that the body is able to extract for use in order to establish the real benefit a consumer derives from the product.

Bioavailability becomes a similarly important question in the consumption of medications, as health researchers and physicians work to determine how much real benefit a patient derives from a drug’s properties and how to improve the body’s use of them. For companies like Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT), enhancing a drug’s bioavailability is part of their bread and butter as they not only develop products designed to improve patients’ quality of life but try to ensure that these products deliver maximum benefit to the human body’s systems.

Pivot Pharmaceuticals’ patents in the field of cannabinoid use comprise a portfolio of landmark technologies that strive to increase bioavailability, drug release rates and product stability so that consumers can “confidently take correct and accurate doses to help meet their health and wellness needs.” Some patents maintain the company’s impetus in making cannabis available through powdered formulations that can be combined with products in the food and beverage market. Through subsidiary Thrudermic (http://cnw.fm/TUSd1), the company is invested in a transdermal lipid-based nano-dispersion technology that enhances skin absorption of cannabinoids, and the company’s water soluble, oral delivery product, PGS-N001, is designed to provide relief to cancer patients suffering from chemotherapy-induced vomiting, nausea, neutropenia and anemia by utilizing a bioavailability technology already demonstrated in Europe.

Market forecasts anticipate that the therapeutic product derivatives of cannabis will fuel a $55.8 billion market by 2025 as a growing number of governments legalize the oft-controversial drug’s use, according to a report issued last year by Grand View Research, Inc. (http://cnw.fm/0ybHh).

Pivot Pharmaceuticals’ innovations in the marketplace are driven by a leadership team that’s experienced in clinical, commercial, product development and financial management. CEO Patrick Frankham has over 20 years of experience in the pharmaceutical, biopharmaceutical and services industries, leading successful development programs in oncology, and he has been a founder, investor and board member of several health care ventures during the past 15 years.

“Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of bio-cannabis products,” Frankham stated in summarizing the company’s mission (http://cnw.fm/cS0Ct).

Board of Directors Chairman Ahmad Doroudian founded Merus Labs International Inc., and he has also filled executive positions for other pharmaceutical companies as part of his activities since becoming involved in early stage financing and management of private and publicly listed companies in the 1990s.

Dr. Wolfgang Renz, a business executive with expertise in medical innovation and cross-industry convergence, as well as a physician specializing in hepatology, serves on the board of directors, and accounting administrator Moira Ong serves as the company’s chief financial officer.

In 2017, Pivot’s Canadian leadership created a United States-based entity to take advantage of the increased legalization of the cannabis market in California and other North American locales, accelerating the monetization of the company’s Ready To Infuse Cannabis (“RTIC”) technology for products in the food and beverage industry. Pivot Naturals, LLC is led by President Pat Rolfes and Director of Research and Development Ross Franklin. Rolfes and Franklin led RTIC developer ERS Holdings LLC prior to the acquisition of that company and its patents by Pivot, and they are joined on the Pivot USA executive team by product formulation administrators Joseph Borovsky and Leonid Lurya, who were the scientific technology executives on the Thrudermic team upon its acquisition.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

• Strong Leadership Team Guides EVIO, Inc. (EVIO) toward 2018 Goal of Opening 18 Cannabis Testing Labs
• Earth Science Tech, Inc. (ETST) Accelerates the Development and Commercialization of Products
• EVIO, Inc. (EVIO) Puts Cannabis Quality and Safety to the Test

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$DTRM President, CEO and Director Patrick Stakenas Featured in Nationwide Media

Business Rockstars, the Largest Platform for Entrepreneurs, Highlights the Advice and Accomplishments of Determine’s Source-to-Pay Visionary in Markets Across the US

CARMEL, Ind., April 05, 2018 – Determine, Inc. (NASDAQ:DTRM), a pioneering leader in global Source to Pay and Enterprise Contract Lifecycle Management (ECLM) Cloud Platform solutions, announced today that President, Chief Executive Officer and Director Patrick Stakenas will be featured on Business Rockstars in coast-to-coast distribution beginning the week of April 9.

Mr. Stakenas, who in addition to spearheading the creation of Determine by combining industry leaders Iasta, b-pack and Selectica, has amassed extensive career accomplishments as an entrepreneur, business owner and industry executive. His segment on Business Rockstars offers real-world advice for aspiring entrepreneurs on how to make critical decisions that lead to success.

Business Rockstars brings together the biggest and most accomplished CEO’s, entrepreneurs, celebrities, small business owners, innovators, and disruptors, providing a daily television, radio, and online show that reaches millions of people around the world. Mr. Stakenas’ interview and segment will run across the entire media platform, including 125 US airports, 150 radio markets, leading hotels and over 43 million households.

About Business Rockstars
“Business Rockstars” is the biggest entrepreneur platform on the planet. It produces video and audio content by award winning content creators and influencers. Business Rockstars is connecting and growing a community of “wantrepreneurs” and entrepreneurs on television, radio, podcast & social media. “Business Rockstars” shows are produced from their Burbank studios, with remote video broadcast facilities in New York and San Francisco, through strategic partner, NASDAQ Private Market. Business Rockstars can be seen in 43 million TV households, 150 Radio markets, Dash Radio, all major podcast platforms, with over 1 million social media followers. Business Rockstars digital content can be seen on Entrepreneur, Yahoo Finance, MSN, businessrockstars.com.

Supporting Resources

Determine Blog

Determine on LinkedIn

Determine on Twitter

Determine Resources

About Determine, Inc.
Determine, Inc. (NASDAQ:DTRM) is a leading global provider of SaaS Source-to-Pay and Enterprise Contract Lifecycle Management (ECLM) solutions. The Determine Cloud Platform provides procurement, legal and finance professionals analytics of their supplier, contract and financial performance. Our technologies empower customers to drive new revenue, identify savings, improve compliance and mitigate risk.

The Determine Cloud Platform seamlessly integrates with major ERP or third-party systems such as SAP, Oracle, Sage, QAD and Microsoft. Modular solutions can be configured to add more as needed to provide additional value beyond spend management. Our unified master database and business process approach empower users at every level to make more informed and smarter decisions.

For more information, please visit: www.determine.com.

Contact

Media Relations:
Mike Mitchell
Determine, Inc.
+1.650.532.1590
pr@determine.com

$VSQTF NetworkNewsAudio Announces Audio Press Release on Virtual Reality and Blockchain

New York, New York–(April 5, 2018) – NetworkNewsAudio announces the Audio Press Release (APR) titled “This Could Be the Year Virtual Reality Conquers the Tech World,” featuring Victory Square Technologies, Inc. (CSE: VST) (OTC Pink: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8).

To hear the NetworkNewsAudio version, visit http://nnw.fm/ZwhR1

To read the original editorial, visit http://nnw.fm/mI9Md

In the realm of advertising, the promise of VR-based marketing like the Chrysler campaign and its potential integration with blockchain — an area in which Victory Square Technologies (OTC: VSQTF) (CSE: VST) is already an expert in — have unreal potential. The company has already invested and incubated numerous businesses in the blockchain tech space, but it also has an existing VR project in the fast-growing VR gaming industry, so it’s no stranger to either technology. Victory Square chose Flo Digital, because it’s currently building out the first-ever blockchain-based VR advertising technology platform.

According to experts, a VR-blockchain combination could spark a digital advertising revolution by solving many common problems encountered in this space such as data transparency, ad fraud and misuse of money spent on advertisements. A possible solution is for platforms to record and measure people’s interaction with VR ads and make payments to content owners accordingly. The whole process could be done on blockchain’s secure, accurate and transparent curation of data, saving money for all involved.

About Victory Square Technologies Inc.

Victory Square is a venture builder that creates, funds and empowers entrepreneurs predominantly focused on blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources and other forms of operational support to help them scale internationally. For more information, visit www.VictorySquare.com.

About NetworkNewsAudio

NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) is another NetworkNewsWire (NNW) Solution that can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$ETST Accelerates the Development and Commercialization of Products

April 5, 2018

• Company announces its membership in Défi Montréal, Canada’s largest business acceleration program
• Partnership with Laboratories BNK Canada, Inc. allows ETST to commercialize its new testing services more quickly
• Strategic acquisition aimed at improving access to funding for development of treatments for various diseases

Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotechnology company that operates in the fields of hemp cannabinoids, nutraceuticals, pharmaceuticals and medical devices, is taking active measures to accelerate its development and growth. On March 22, 2018, ETST announced its membership in the 16th cohort of Défi Montréal, the largest innovative business acceleration program in Quebec. Martin Duchaîne, founder of Défi Montréal, has advised or assisted over 900 entrepreneurs in his 20-year career. This new membership is expected to accelerate the development and commercialization of new ETST products in Canada and overseas (http://cnw.fm/J5fFa).

Through ETST’s connection with Défi Montréal, key individuals have already been brought on board to advance the acceleration of operations. In January 2018, ETST announced a deal with Laboratories BNK Canada, Inc. for clinical studies related to the MSN-2 medical device. The MSN-2 is a home kit designed for the detection of sexually transmitted infections (STIs) from a self-obtained gynecological specimen. MSN-2 has been confirmed through studies to detect chlamydia. The company is working to validate similar results for gonorrhea. Testing for trichomoniasis, as well as different serotypes of the human papillomavirus (HPV), are expected to be added in the near future. Partnering with Laboratories BNK offers ETST an accelerated plan of development for more products while cutting costs and, ideally, treating more patients. This arrangement gives ETST the means to accelerate the commercialization of its new testing services while it works toward its ultimate goal of halting the spread of STIs.

ETST holds three wholly owned subsidiaries, including Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and KannaBidioid Inc. In 2017, ETST acquired Canna Inno Laboratories Inc. as a strategic move that gave ETST access to government grants. The first of these grants was awarded from the Government of Québec for innovation in the pharmaceutical industry and will support the pre-launch process of ETST’s three CBD-based products that aim to prevent common causes of cancer and help reduce occurrence rates.

ETST strives to discover solutions for conditions with no current effective treatment, targeting diseases for which the benefits of CBD have been demonstrated by researchers worldwide. The move to accelerate the development and commercialization of these products is an effort to improve treatments for different diseases on a global scale.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

• EVIO, Inc. (EVIO) Puts Cannabis Quality and Safety to the Test
• Xanthic Biopharma Inc. Establishing a New Paradigm in Cannabinoid Delivery
• ChineseInvestors.com, Inc. (CIIX) to Debut ‘Bitcoin Big Winner’ Program on Phoenix North America Chinese Channel

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$NETE Subsidiary Launches New Same-Day Funding Service

Contact:
Net Element, Inc.
media@netelement.com
+1 (786) 923-0502

$TENX Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan

MORRISVILLE, N.C.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addressed the Company’s questions and provided guidance on its upcoming Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF).

The FDA agreed that the new Phase 2 clinical protocol can be submitted under the existing IND, and supported the study design and endpoints for demonstrating proof-of-concept in PH-HFpEF patients.

“We are very pleased with the outcome of the pre IND meeting,” said Michael Jebsen, Interim CEO of Tenax. “The initial pathway to move forward with the development of levosimendan in PH-HFpEF has been clarified and confirmed. We will finalize our Phase 2 clinical trial protocol for IND submission and continue preparations for a late June or July start of the trial.”

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on licensing, development, and commercialization of drugs that address conditions with high unmet medical need. The Company has a world-class scientific team including recognized global experts in pulmonary hypertension. The Company owns the North American rights to develop and commercialize levosimendan and is finalizing preparations to begin their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) early in the second half of 2018. For more information, visit www.tenaxthera.com.

About Levosimendan

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and not available in the United States. Tenax Therapeutics acquired the North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to matters beyond the Company’s control that could lead to delays in the clinical study, delays in new product introductions and customer acceptance of these new products, matters beyond the Company’s control that could impact the Company’s continued compliance with Nasdaq listing requirements, and other risks and uncertainties as described in the Company’s filings with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on April 2, 2018 and its other filings with the SEC. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Statements in this press release regarding management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

$VSQTF NetworkNewsWire Publication on Cutting-Edge and Immersive VR/AR Experiences

NetworkNewsWire Editorial Coverage: Ever since it was introduced five years ago, virtual reality (VR) technology has been underwhelming due to the lack of content and the exuberant costs of headsets like Oculus. But this year, the VR market could grow by 25 percent, according to the Consumer Technology Association, thanks to new products announced by Google and others in the tech world. VR enthusiasts are also predicting that Steven Spielberg’s newest film, which depicts a futuristic VR universe, could push the technology into mainstream. However, the biggest boost to VR technology potentially comes from the integration of blockchain technology. This is where blockchain companies could bring the true potential of VR into life. Companies at the forefront of this technology include Victory Square Technologies, Inc. (OTC: VSQTF) (CSE: VST) (VSQTF Profile), 360 Blockchain, Inc. (CSE: CODE), Hashchain Technology, Inc. (TSX-V: KASH), BTCS, Inc. (OTC: BTCS), and Marathon Patent Group, Inc. (NASDAQ: MARA).

At the recent Game Developers Conference in San Francisco, tech giants such as Facebook, Sony and Google all advocated for VR technologies. According to Forbes (http://nnw.fm/RyP8D), the biggest takeaway from this conference is that there was less talk about experimental VR and more about commercial VR, such as in advertising. Clearly, the VR market is on a trajectory into a new era. Based on reports from Business Insider, it is estimated that the VR market will grow from $2 billion to $27 billion between 2016 and 2022 (http://nnw.fm/Fc44G).

Recognizing that VR could finally become a mainstream consumer technology, Victory Square Technologies landed a arrangement last week to acquire 49% (percent) of Flo Digital Inc., a VR advertising experience platform with access to over 200 million monthly viewers across North America. Flo Digital’s VR network already spans several platforms, including HTC VIVE, Google Cardboard, Google Daydream, IOS, Android and Web VR. One of its latest VR projects was a collaboration with Chrysler Canada, which allowed users to virtually test drive the all-new Challenger.

Blockchain Unlocks Unreal Potential in Advertising

In the realm of advertising, the promise of VR-based marketing like the Chrysler campaign and its potential integration with blockchain — an area in which Victory Square Technologies (OTC: VSQTF) (CSE: VST) is already an expert in — have unreal potential. The company has already invested and incubated numerous businesses in the blockchain tech space, but it also has an existing VR project in the fast-growing VR gaming industry, so it’s no stranger to either technology. Victory Square chose Flo Digital, because it’s currently building out the first-ever blockchain-based VR advertising technology platform.

According to experts, a VR-blockchain combination could spark a digital advertising revolution by solving many common problems encountered in this space such as data transparency, ad fraud and misuse of money spent on advertisements. A possible solution is for platforms to record and measure people’s interaction with VR ads and make payments to content owners accordingly. The whole process could be done on blockchain’s secure, accurate and transparent curation of data, saving money for all involved.

Procter & Gamble made headlines last year for threatening to pull $2.4 billion in ad spending because of ongoing ad fraud and transparency issues, even calling out its partner Facebook.

P&G’s chief brand officer Marc Pritchard stated at the time: “There is, we believe, at least 20 percent to 30 percent of waste in the media supply chain because of lack of “viewability,” non-transparent contracts, non-transparent measurement of inputs, fraud, and now even your ads showing up in unsafe places.” The solution to this is a combination of VR (better user experience) and blockchain (transparency).

Google is already encouraging developers to work with a VR prototype to replace traditional advertising, and so have Apple and Microsoft. This presents a big opportunity for companies such as Victory Square Technologies (OTC: VSQTF) (CSE: VST) with strong footprints in both VR and blockchain to make a technological breakthrough with its potentially first-of-its-kind Flo Digital platform.

Commenting on its newest VR-blockchain acquisition, Shafin Diamond Tejani, Victory Square CEO, said: “Flo Digital has a proven track record of providing cutting-edge and immersive VR/AR experiences to leading brands that include Chrysler Canada, Warner Bros. and Rogers Wireless, to name a few. It is this calibre of customers and execution that makes the entire team at Victory Square eager to work with Flo Digital on their next stage of growth.

“This represents another investment in the VR/AR industry and further illustrates our thesis that blockchain technology will disrupt the existing landscape in ad tech and ultimately change the way brands will connect with their customers,” Tejani added.

Other Players in the Blockchain Space

360 Blockchain (CSE: CODE) is building an all-round blockchain ecosystem that includes cryptocurrencies, smart contracts and data management. In December, the company announced its intention to invest in Arcology, a platform that uses machine learning and pattern recognition technology to create hierarchical blockchain structures. Recently, 360 Blockchain completed its acquisition of a 60 percent stake in SV CryptoLab, a Silicon Valley-based crypto facility.

Hashchain Technology (TSX-V: KASH) is the first public cryptocurrency mining company to file a final prospectus in Canada supporting highly scalable and flexible mining operations across all major cryptocurrencies. Last month, the company completed the acquisition of NODE40 LLC, which comprises a team of experienced blockchain experts and software engineers.

BTCS (OTC: BTCS) is one of the first public companies in the United States to be involved with digital assets and blockchain technologies. The company plans to create a portfolio of digital assets including Bitcoin and other “protocol tokens.” It has an agreement in place to merge with Blockchain Global Ltd., an Australian blockchain company.

Marathon (NASDAQ: MARA) is focused on acquiring patents and patent rights from individual owners and Fortune 500 companies. The company monetizes its portfolio by entering licensing deals. Earlier this year, Marathon entered a purchase agreement to acquire four patents related to the transmission and exchange of cryptocurrencies between buyers and sellers.

Spielberg’s New Film Could Ignite a VR Tech Fever

Although VR technology is still at an infancy stage, it is also about to receive a big lift in the real world thanks to Steven Spielberg’s highly anticipated ”Ready Player One” — centered around a utopian VR future — hitting theatres on March 29. Like previous Hollywood releases that have produced remarkable marketing results (i.e., The Blues Brothers was credited for boosting sunglasses sales in the 1980s), this film will give the audience a grandiose visualization of the infinite possibilities created by VR technology, which transcend real-life experiences, potentially helping to ignite a VR fever that already seems to be gaining traction.

This signals an ideal time for companies to delve deeper into this tech space, much like Victory Square Technologies has just done with the Flo Digital acquisition. Now that Spielberg’s next big release is set to become a big marketing campaign for VR, the next step is to realize the technology’s true potential in advertising through the help of blockchain.

Imagine a platform that charges advertisers solely on the amount of time consumers were immersed in the VR content and rewards content producers accordingly, with all transactions safely recorded on blockchain. A VR-blockchain integration could finally eliminate the 20 to 30 percent waste resulting from inefficient advertising, and Victory Square Technologies could be the one to bring that kind of platform into life.

For more information on Victory Square Technologies Inc. (OTC:VSQTF) (CSE:VST), please visit StreetSignals.com for a free research report.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

$PVOTF Posts Product Development Update

VANCOUVER, April 4, 2018 – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”) is pleased to provide a corporate update on the advancements of its industry leading bio-cannabis product pipeline. As previously announced, a 1% CBD Oral Micelle Solution developed in Germany is ready-to-market and development of two topical creams using the Company’s patented formulation and delivery systems is now complete.

In light of this development, the Company is anticipating that it will have several products available for sale in Canada on the date legalization officially begins. Pivot also projects to begin sales in California as of Q3 2018, including the launch of its proprietary line of “Ready-to-Infuse-Cannabis” (“RTIC”) natural health products. The sale of bulk powder, stick packs and capsules is expected to drive significant revenue.

The patents secured to date provide a significant opportunity for Pivot to create proprietary products that are unmatched in quality by current licensed producers and product distributors. The Company’s Intellectual Property portfolio covers several key patent areas which have previously demonstrated their ability to deliver pharmaceutical grade products in clinical trials. Pivot will now manufacture and commercialize its pipeline in anticipation of the legalization of cannabis in Canada as well as internationally, where regulations permit.

Pivot’s differentiated business model has entailed acquiring disruptive drug formulation and delivery technologies and then to develop dosable and reproducible bio-cannabis products for consumers. Pivot’s patent  protected products will enable the Company to secure sales free from competitors claiming similar activities.  According to the World Intellectual Property Organization (WIPO) pursuing a patent strategy allows Pivot to have:

• Exclusive rights
• Strong market position
• Higher returns on investment
• Opportunities to license or sell Inventions
• Have a strong negotiation position with companies that may infringe

Dr. Joseph Borovsky, Pivot’s Vice President, Formulations, indicates that “our development team in Israel has now completed key development milestones with our nanoparticulate transdermal technology product as well as with our BiPhasix topical product.  These two lead product candidates will complete final testing and we will announce our scale-up and marketing strategy in the coming months.”

“Canadian Licensed Producers have invested extensively in dried flower and oil production capacity but have not focused on downstream sustainable quality products made from cannabis. Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of  bio-cannabis products,” said Dr. Patrick Frankham, Pivot’s CEO.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, project, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc. or Pivot Green Stream Health Solutions Inc., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

$ETST Subsidiary Demonstrates Innovation in the Pharmaceutical Industry

March 13, 2018

• Received grant from Government of Québec through Canno Inno Laboratories subsidiary
• Canna Inno Laboratories enhances collaboration between the company’s resources in Canada and the U.S. while providing access to grants
• Sound scientific research and transparent studies

Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotechnology company focused on cannabis, industrial hemp and cannabinoid research and development for nutraceuticals, pharmaceuticals and medical devices, announced last week that its subsidiary, Canna Inno Laboratories Inc., has received a grant from the Government of Québec for innovation in the pharmaceutical industry. ETST plans to apply for additional funding under Canada’s Scientific Research and Experimental Development Tax Credit program (http://nnw.fm/YN2cr).

Earth Science Tech formed Canna Inno Laboratories, Inc. in 2017. Strategically headquartered in Montreal, Quebec, it allows Earth Science Tech access to Canadian government and private grants offered to companies for innovation in the pharmaceutical industry. The awarded grant will support the pre-launch process of Earth Science’s three CBD-based products. These nutraceutical products aim to prevent common causes of cancer and help reduce occurrence rates. The pre-launch process includes a series of pre-clinical in vitro trials to fight breast cancer and neurodegenerative disorders. Once complete and patent pending, these high-grade hemp CBD oil products will be commercialized as nutraceuticals and provide alternative natural treatment solutions.

Through the in vitro study with the University of Central Oklahoma and DV Biologics, ETST has provided results that confirm the positive effect of its CBD on breast cancer, immune cell function and human brain cells. The goal of ETST is to discover solutions for conditions that currently have no effective treatment, targeting diseases in which the benefits of CBD have already been demonstrated by researchers worldwide. ETST seeks to increase the effectiveness of cannabinoids and/or CBD and thereby improve treatments for different diseases. The company focuses on providing sound scientific research and transparency on the progression of studies done on its highest quality and purity, full spectrum high-grade hemp CBD products.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

• Xanthic Biopharma Inc. Establishing a New Paradigm in Cannabinoid Delivery
• Petroteq Energy Inc.’s (TSX.V: PQE) (OTCQX: PQEFF) Proprietary Oil Extraction Technology Favors the Environment
• OTC Markets Group Cracks Down on Manipulative and Misleading Stock Promotion

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CIIX to Present at The MicroCap Conference on April 9th and 10th in New York City

SAN GABRIEL, California, April 4, 2018 —

ChineseInvestors.com Inc. (OTCQB: CIIX)(“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, announces that will be presenting at this year’s MicroCap Conference on April 9th and 10th in New York City.

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. Conference attendees are provided the opportunity to interact with management at some of the most attractive small companies, to learn from the various expert panels, and to mingle with other microcap investors.

At the conference, ChineseInvestors.com, Inc.’s CEO Warren Wang will present information regarding the Company’s business updates including its developing cryptocurrency business which focuses on three areas: Cryptocurrency Media & Education Services; Cryptocurrency ATMs and Mining.

In November 2017 the Company launched http://www.newcoins168.com , a premier Chinese cryptocurrency and blockchain technology information and education platform providing straightforward explanation of cryptocurrency basics, trading guidelines, real-time market commentary and analysis regarding mining, blockchain technology, industry hotspots, sec-tor-related stock trends and ETFs, and other strategies and opportunities to capitalize on this growing market.

The Company also provides a Bitcoin ATMs with on-site customer service representatives providing instruction in both Chinese and English. In addition, the Company is exploring investments in Cryptocurrency Mining with its recent purchase of ASIC (Application Specific Integrated Circuit) machines used to mine SHA-256 or Scrypt mining algorithms to earn cryptocurrencies such as Bitcoin and Litecoin.

“We look forward to providing attendees with information regarding the Company’s cryptocurrency business and welcome this opportunity to network with leading micro-cap and small-cap professionals,” says CIIX founder and CEO Warren Wang.

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Visit and register https://www.newcoins168.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Subscribe and watch our video commentaries: https://www.youtube.com/channel/UCriTFjFHCvDW_LBhiIeuLlQ/featured

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776
Investor Relations:
Alan Klitenic
+1-214-636-2548
Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+1-212-418-1217 Office
Editor@NetworkNewsWire.com

$BPTH Interim Data from Phase 2 Clinical of Prexigebersen in AML

 Prexigebersen plus LDAC was well-tolerated and showed early anti-leukemic activity in nearly 50% of evaluable AML patients treated to date

Planned protocol amendments may provide for potential approvals in the U.S. and Europe of two prexigerbesen combination treatments

HOUSTON, April 03, 2018 — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces that interim data from its Phase 2 study of prexigebersen in combination with low-dose cytarabine (LDAC) (BP1001-201) for the treatment of acute myeloid leukemia (AML) has demonstrated that the combination therapy continues to be well-tolerated and has shown early anti-leukemic activity in nearly 50% of evaluable AML patients including four patients with complete remission and four with stable disease to date in this study.

The open-label Phase 2 study is evaluating the efficacy and safety of prexigebersen in conjunction with LDAC, a therapeutic regimen well established in treatment of AML patients who cannot or elect not to be treated with more intensive chemotherapy.  The primary objective of the study is to determine whether the combination of prexigebersen and LDAC provides greater efficacy than what would be expected with LDAC alone in this de novo patient population.  The study had a pre-determined decision point at 19 evaluable patients in which the study would be terminated if less than 5 patients responded and the study would be expanded to 54 patients if five or more patients responded.

The interim analysis was performed on 17 evaluable patients instead of 19, since criteria to move to the next steps in the study had been met.  Of the 17 evaluable patients, there were four patients who achieved complete responses, one patient who achieved a morphologic leukemia free state, two patients who had significantly reduced bone marrow blasts and four patients with stable disease.  In total, 47% of the evaluable patients showed some form of response, including stable disease, to the combination treatment. The average age of patients in the study was 73.5 years old.

Based on the recommendations of the principal investigators of the study, the Company is  amending the protocol to change the dosing schedule to that used in the Phase 1b study in relapsed and refractory AML patients in which a higher dose of prexigerbesen was administered prior to LDAC treatment starting at day 10 versus LDAC treatment starting on day four as was the case in the BP1001-201 study to date.  In addition, the investigators endorse the inclusion of a decitabine cohort based on relatively new and positive data with this compound.

“We are very pleased with these encouraging interim data as they demonstrate the potential for the combination of prexigerbesen and LDAC to effectively treat these de novo AML patients.  These early results are encouraging when you consider that the complete response rate in elderly AML patients greater than 65 years of age on LDAC alone have been estimated (Lin Journal of Clinical Oncology Abstract) to be only 10%¹,” noted Peter H. Nielsen, chief executive officer of Bio-Path.  “We look forward to advancing the planned protocol amendments as we expect they will provide even better results for these patients suffering with AML.  If successful, it will provide for approvals in the U.S. and Europe for both combination therapies.”

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company’s website at http://www.biopathholdings.com.

References
¹ Lin, T. (2016). Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia. Journal of Clinical Oncology. 34(15). doi: 10.1200/JCO.2016.34.15_suppl.7007

Contact Information:

Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

$MYND Completes $2.1 Million Dollar Private Placement by Company Insiders

MISSION VIEJO, Calif., April 03, 2018 — MYnd Analytics, Inc. (NASDAQ:MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced that it completed a private placement for gross proceeds of $2.1 million (the “Financing”) on March 29, 2018.  The Company sold an aggregate of 1,050,000 units for $2.00 per unit (the “Units”), each consisting of one share of newly-designated Series A Preferred Stock (the “Series A Preferred Stock”) and one Warrant (the “Warrants”) to purchase one share of Common Stock (“Common Stock”) for $2.34 per share to three affiliates of the Company. The closing price per share of the Common Stock on the Nasdaq Stock Market on March 29, 2018 was $1.19 per share.

Shares of the Company’s Series A Preferred Stock will be entitled to receive cash dividends at the rate of five percent (5.00%) of the Original Series A Issue Price per annum. The Warrants will be exercisable for a period of five years for an exercise price of $2.34. The exercise price is subject to adjustment for stock splits, stock dividends, combinations or similar events. The Warrants may not be exercised on a cashless basis.

In connection with the Financing, MYND also entered into a registration rights agreement (the “Registration Rights Agreement”) with the investors, requiring MYND to register the resale of the shares of Common Stock underlying the preferred stock and the Warrants. The Company expects to use the proceeds of the Financing for general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

A complete and detailed description of the Agreement and related registration rights agreement is set forth in MYND’ Current Report on Form 8-K, filed today with the Securities & Exchange Commission.

About MYnd Analytics

MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 39,000 outcomes for over 11,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.

MYnd also operates its wholly owned subsidiarity Arcadian Telepsychiatry Services, LLC which manages a suite of services including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. Arcadian utilizes patient engagement and re-engagement strategies so that care is effectively completed, helping to comfortably move inpatient care to outpatient, assisting patients in readjusting to their life routine, as well as reducing wait times for mental health treatment. Arcadian’s customer base includes major health plans, health systems, and community-based organizations.

Forward-looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as MYnd’s ability to successfully expand into various market channels, the ability of its products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses and MYnd’s ability to expand globally in areas where there is an opportunity to improve treatment in mental health, to continue to protect and enforce its patents, as well as those risks and uncertainties set forth in MYnd’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein. 

To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.

Contact:

Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: mynd@crescendo-ir.com

$CASI To Present At The H.C. Wainwright Global Life Sciences Conference

ROCKVILLE, Md., April 3, 2018 — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces it will present at the H.C. Wainwright Global Life Sciences Conference, April 8 – 10, 2018 in Monte Carlo, Monaco.

Presentation details are below:

Event:  H.C. Wainwright Global Life Sciences Conference
Date:  Tuesday, April 10, 2018
Time:  4:15 – 4:40 p.m. Local Time
Presenter: Ken K. Ren, Ph.D., Chief Executive Officer
Presentation Room:  Salon Atlantic-W (2^nd Floor), Le Meridien Beach Plaza Hotel, Monte Carlo

A copy of the presentation materials will be made available directly through the Investor Relations section of the company’s website, www.casipharmaceuticals.com, on April 10, 2018.

About CASI Pharmaceuticals, Inc.

CASI is a U.S. based biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients. CASI’s product pipeline features (1) EVOMELA^®, MARQIBO^®, and ZEVALIN^®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory process for market approval in China, (2) an acquired portfolio of 25 FDA-approved abbreviated new drug applications (ANDAs), one ANDA that was tentatively approved and three ANDAs that are pending FDA approval, from which CASI will prioritize a select subset for product registration and commercialization in China, (3) our proprietary drug candidate, ENMD-2076, currently in Phase 2 clinical development, and (4) proprietary early-stage candidates in immuno-oncology preclinical development.  CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China.  More information on CASI is available at www.casipharmaceuticals.com and in the Company’s filings with the U.S. Securities and Exchange Commission.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.  Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, the difficulty of executing our business strategy in China; the risk that we will not be able to effectively select, register and commercialize products from our recently acquired portfolio of ANDAs; our inability to predict when or if our product candidates will be approved for marketing by CFDA authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

EVOMELA^®, MARQIBO^®, and ZEVALIN^® are proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.

$VSQTF This Could Be the Year Virtual Reality Conquers the Tech World

April 3, 2018

NetworkNewsWire Editorial Coverage: Ever since it was introduced five years ago, virtual reality (VR) technology has been underwhelming due to the lack of content and the exuberant costs of headsets like Oculus. But this year, the VR market could grow by 25 percent, according to the Consumer Technology Association, thanks to new products announced by Google and others in the tech world. VR enthusiasts are also predicting that Steven Spielberg’s newest film, which depicts a futuristic VR universe, could push the technology into mainstream. However, the biggest boost to VR technology potentially comes from the integration of blockchain technology. This is where blockchain companies could bring the true potential of VR into life. Companies at the forefront of this technology include Victory Square Technologies, Inc. (OTC: VSQTF) (CSE: VST) (VSQTF Profile), 360 Blockchain, Inc. (CSE: CODE), Hashchain Technology, Inc. (TSX-V: KASH), BTCS, Inc. (OTC: BTCS), and Marathon Patent Group, Inc. (NASDAQ: MARA).

At the recent Game Developers Conference in San Francisco, tech giants such as Facebook, Sony and Google all advocated for VR technologies. According to Forbes (http://nnw.fm/RyP8D), the biggest takeaway from this conference is that there was less talk about experimental VR and more about commercial VR, such as in advertising. Clearly, the VR market is on a trajectory into a new era. Based on reports from Business Insider, it is estimated that the VR market will grow from $2 billion to $27 billion between 2016 and 2022 (http://nnw.fm/Fc44G).

Recognizing that VR could finally become a mainstream consumer technology, Victory Square Technologies landed a arrangement last week to acquire 49% (percent) of Flo Digital Inc., a VR advertising experience platform with access to over 200 million monthly viewers across North America. Flo Digital’s VR network already spans several platforms, including HTC VIVE, Google Cardboard, Google Daydream, IOS, Android and Web VR. One of its latest VR projects was a collaboration with Chrysler Canada, which allowed users to virtually test drive the all-new Challenger.

Blockchain Unlocks Unreal Potential in Advertising

In the realm of advertising, the promise of VR-based marketing like the Chrysler campaign and its potential integration with blockchain — an area in which Victory Square Technologies (OTC: VSQTF) (CSE: VST) is already an expert in — have unreal potential. The company has already invested and incubated numerous businesses in the blockchain tech space, but it also has an existing VR project in the fast-growing VR gaming industry, so it’s no stranger to either technology. Victory Square chose Flo Digital, because it’s currently building out the first-ever blockchain-based VR advertising technology platform.

According to experts, a VR-blockchain combination could spark a digital advertising revolution by solving many common problems encountered in this space such as data transparency, ad fraud and misuse of money spent on advertisements. A possible solution is for platforms to record and measure people’s interaction with VR ads and make payments to content owners accordingly. The whole process could be done on blockchain’s secure, accurate and transparent curation of data, saving money for all involved.

Procter & Gamble made headlines last year for threatening to pull $2.4 billion in ad spending because of ongoing ad fraud and transparency issues, even calling out its partner Facebook.

P&G’s chief brand officer Marc Pritchard stated at the time: “There is, we believe, at least 20 percent to 30 percent of waste in the media supply chain because of lack of “viewability,” non-transparent contracts, non-transparent measurement of inputs, fraud, and now even your ads showing up in unsafe places.” The solution to this is a combination of VR (better user experience) and blockchain (transparency).

Google is already encouraging developers to work with a VR prototype to replace traditional advertising, and so have Apple and Microsoft. This presents a big opportunity for companies such as Victory Square Technologies (OTC: VSQTF) (CSE: VST) with strong footprints in both VR and blockchain to make a technological breakthrough with its potentially first-of-its-kind Flo Digital platform.

Commenting on its newest VR-blockchain acquisition, Shafin Diamond Tejani, Victory Square CEO, said: “Flo Digital has a proven track record of providing cutting-edge and immersive VR/AR experiences to leading brands that include Chrysler Canada, Warner Bros. and Rogers Wireless, to name a few. It is this calibre of customers and execution that makes the entire team at Victory Square eager to work with Flo Digital on their next stage of growth.

“This represents another investment in the VR/AR industry and further illustrates our thesis that blockchain technology will disrupt the existing landscape in ad tech and ultimately change the way brands will connect with their customers,” Tejani added.

Other Players in the Blockchain Space

360 Blockchain (CSE: CODE) is building an all-round blockchain ecosystem that includes cryptocurrencies, smart contracts and data management. In December, the company announced its intention to invest in Arcology, a platform that uses machine learning and pattern recognition technology to create hierarchical blockchain structures. Recently, 360 Blockchain completed its acquisition of a 60 percent stake in SV CryptoLab, a Silicon Valley-based crypto facility.

Hashchain Technology (TSX-V: KASH) is the first public cryptocurrency mining company to file a final prospectus in Canada supporting highly scalable and flexible mining operations across all major cryptocurrencies. Last month, the company completed the acquisition of NODE40 LLC, which comprises a team of experienced blockchain experts and software engineers.

BTCS (OTC: BTCS) is one of the first public companies in the United States to be involved with digital assets and blockchain technologies. The company plans to create a portfolio of digital assets including Bitcoin and other “protocol tokens.” It has an agreement in place to merge with Blockchain Global Ltd., an Australian blockchain company.

Marathon (NASDAQ: MARA) is focused on acquiring patents and patent rights from individual owners and Fortune 500 companies. The company monetizes its portfolio by entering licensing deals. Earlier this year, Marathon entered a purchase agreement to acquire four patents related to the transmission and exchange of cryptocurrencies between buyers and sellers.

Spielberg’s New Film Could Ignite a VR Tech Fever

Although VR technology is still at an infancy stage, it is also about to receive a big lift in the real world thanks to Steven Spielberg’s highly anticipated ”Ready Player One” — centered around a utopian VR future — hitting theatres on March 29. Like previous Hollywood releases that have produced remarkable marketing results (i.e., The Blues Brothers was credited for boosting sunglasses sales in the 1980s), this film will give the audience a grandiose visualization of the infinite possibilities created by VR technology, which transcend real-life experiences, potentially helping to ignite a VR fever that already seems to be gaining traction.

This signals an ideal time for companies to delve deeper into this tech space, much like Victory Square Technologies has just done with the Flo Digital acquisition. Now that Spielberg’s next big release is set to become a big marketing campaign for VR, the next step is to realize the technology’s true potential in advertising through the help of blockchain.

Imagine a platform that charges advertisers solely on the amount of time consumers were immersed in the VR content and rewards content producers accordingly, with all transactions safely recorded on blockchain. A VR-blockchain integration could finally eliminate the 20 to 30 percent waste resulting from inefficient advertising, and Victory Square Technologies could be the one to bring that kind of platform into life.

For more information on Victory Square Technologies Inc. (OTC:VSQTF) (CSE:VST), please visit StreetSignals.com for a free research report.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

$PBIO Fourth Quarter, Fiscal Year 2017 Financial Results, Business Update

Instrument and Consumable Sales Show Continued Double-Digit Growth in Q4 and FY2017; Total Annual Revenue Exceeds $2 Million for First Time

2017 New Product Releases, CE Marking, GMP Compliance, Acquisition of BaroFold Assets, Initial UST Patents & Significant Expansion of Sales & Marketing Capabilities Expected to Fuel Growth in FY2018

Investor Conference Call Scheduled for Tuesday, April 3, 2018 at 4:30 PM EDT

SOUTH EASTON, MA / April 3, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2017, provided a business update, and offered limited guidance for FY2018.

Financial Results: Q4 2017 vs. Q4 2016

Products and services revenue was $455,767 for the fourth quarter of 2017 compared to $365,262 for the same quarter of 2016, a 25% increase. Sales of instruments increased to $317,498 in Q4 2017 compared to $204,460 in Q4 2016, an increase of 55%. Sales of consumables were $60,108 for the fourth quarter of 2017 compared to $50,054 for the same period in 2016, a 20% increase. Grant revenue in Q4 2017 was $46,941 compared to $54,449 in Q4 2016.

Total revenue for the fourth quarter ended December 31, 2017 was $502,708 compared to $419,711 for the same period in 2016, a 20% increase. This increase was primarily due to our double-digit growth in products and services.

Operating loss for Q4 2017 was $1,318,384 compared to $1,177,205 for the same period in 2016. This increase in operating loss was primarily due to increases in sales and marketing expenses related to the expansion of our field sales team from one to five individuals during FY2017, as well as to an inventory allowance in FY2017 of $159,600.

Loss per common share – basic – was $2.37 for Q4 2017 compared to income per common share of $3.13 for the same period in 2016. Loss per common share – diluted – was $2.37 for Q4 2017 compared to loss per common share of $0.64 for the same period in 2016.

Financial Results: FY2017 vs. FY2016

Products and services revenue was $2,065,891 for the year ended December 31, 2017 compared with $1,794,749 for the year ended December 31, 2016, a 15% increase. Sales of instruments increased to $1,459,326 for FY2017 compared to $1,205,520 for FY2016, an increase of 21%. Sales of consumables were $260,331 for the year ended December 31, 2017 compared to $199,873 for the same period in 2016, an increase of $60,458 or 30%. Grant revenue for fiscal year 2017 was $174,607 compared to $181,738 for the 2016 fiscal year.

Total revenue for FY2017 was $2,240,498 compared to $1,976,487 for FY2016, a 13% increase. This increase was primarily due to our double-digit growth in products and services.

Operating loss for FY2017 was $4,647,048 compared to $3,735,653 for FY2016. This increase was primarily due to increases in sales and marketing expenses related to the build-out of a field sales force, an inventory allowance of $159,600, and the one-time administrative credits in the prior year, off-set to a certain extent by increases in total revenue.

Loss per common share – basic and diluted – was $9.62 for FY2017 and $2.97 for the 2016 fiscal year.

Operational & Technical Highlights: FY2017

• A significant software upgrade for our flagship Barocycler 2320EXTREME has brought our next-generation PCT-based instrument to GMP and GLP compliance, which in turn should open many new doors in the biopharmaceutical manufacturing and drug discovery & development areas of the very large life sciences field.

• The acquisition of all assets of BaroFold Corporation combines BaroFold’s patented high-pressure protein refolding technology (PreEMT) with PBI’s leadership in high-pressure instrumentation and worldwide market access, which will allow PBI entry into the Biologics Contract Research Services Sector.

• Professor Tiannan Guo’s laboratory at the world famous Westlake Institute for Advanced Study was named PBI’s first Center of Excellence in China, which we believe should support an aggressive marketing and sales strategy in China, which in turn could drive significant expansion in China and the rest of Asia.

• We believe our strategic collaboration with Phasex Corporation will allow us to address broad markets for stable, water-soluble nanoemulsions. We expect the combination of our recently patented Ultra Shear Technology (UST) with Phasex’s Supercritical Fluid processing methods will enable development of stable, water-soluble nanoemulsions, including CBD-enriched plant oil.

• We were issued the first two patents on our widely-applicable, high pressure-based Ultra Shear Technology. We believe that UST can be used to create or improve a broad range of medical, consumer, and industrial products through the preparation of high-quality nanoemulsions and “clean label” food.

• Our recently-released, next-generation Barocycler 2320EXTREME instrument was named a finalist in the prestigious 2017 R&D 100 Awards. Known as the “Oscars of Innovation”, the R&D 100 Awards recognize the top 100 revolutionary technologies of the past year.

• Professor Ruedi Aebersold, a worldwide expert in proteomics and one of PBI’s most well-known clients, received the prestigious Karger Medal for significant contributions to the development of new bioanalytical methods. In his acceptance speech, he discussed the importance of sample preparation and mentioned his use of the PCT Platform.

• Joseph L. Damasio, Jr. joined the Company as our full-time Chief Financial Officer and Vice President of Finance.

• Our Barocycler 2320EXTREME was named “Best New Instrument for Sample Preparation 2017” by Corporate America News (“Corp America”) as part of the publication’s 2017 North American Excellence Awards.

• We achieved CE Marking for our flagship instrument, the next-generation Barocycler 2320EXTREME. CE Marking permits PBI to begin sales of the 2320EXT to all 31 countries of the European Economic Area.

Mr. Joseph L. Damasio, VP of Finance and CFO of PBI, commented, “This past year was filled with a number of significant financial, operational and technological accomplishments that have set the stage well for what we believe will be a very exciting and successful 2018. Key among these accomplishments are the continued double-digit growth rates in our products and services area, the acquisition of the BaroFold patents, the continued maturation of our novel and now patented Ultra Shear Technology, the critical changes made to our flagship Barocycler 2320EXTREME that have enhanced this already very powerful instrument, the significant expansion of our sales and marketing capabilities, and the continued global recognition of the advantages of the PCT Platform in biological scientific studies.”

Mr. Damasio continued, “Although we had a successful 2017, we were nonetheless disappointed that our goal to up-list PBI to a national exchange did not happen last year. Because we understand the advantages and importance that an up-list will bring PBI, we anticipate re-initiating the up-list process soon, with a goal to complete the up-list before the end of this year.”

Mr. Richard T. Schumacher, President and CEO of PBI, commented, “We believe that the accomplishments of the past several years have set the stage well for future success. Our technology is now more powerful, our customer base bigger, our product portfolio larger, our product applications more enhanced, our supporters more vocal, our capabilities stronger, and our desire to succeed has never been more focused and determined. We remain very, very excited about 2018.”

Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Tuesday, April 3, 2018. To attend this teleconference via telephone, Dial-in: (877) 407-8031 (North America), (201) 689-8031 (International). Verbal Passcode: PBIO Fourth Quarter and Fiscal Year 2017 Financial Call, ID 27377.

Replay Number (877) 481-4010; (919) 882-2331 (International). Teleconference Replay Available for 30 days.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company’s financial results for the year ended December 31, 2017 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS

Investor Contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)
Joseph L. Damasio, VP of Finance and CFO (508) 230-1829 (F)

$CIIX to Debut ‘Bitcoin Big Winner’ Program on Phoenix North America Chinese Channel

April 3, 2018

• Reinforcing its focus on cryptocurrency and TV broadcasts, CIIX recently unveiled plans to broadcast a daily commentary titled ‘Bitcoin Big Winner’ on the Phoenix North America Chinese Channel
• CIIX broadcasts a live daily video show titled ’Bitcoin MultiMillionaire’ from the floor of the NYSE; company plans to explore cryptocurrency mining at datacenter near Seattle
• CIIX sponsored 2018 National Investment Bankers Association (“NIBA”) meeting in New York to meet with micro-cap and small-cap investors

ChineseInvestors.com, Inc. (OTCQB: CIIX) is reaching the global Chinese-speaking community with regard to bitcoin — with TV broadcasts, an online site, an ATM in the lobby of its San Gabriel, California, headquarters and plans to mine cryptocurrency from a datacenter near Seattle. The company is exploring cryptocurrency mining following its recent purchase of mining machines (http://cnw.fm/VL4nB).

CIIX recently sponsored the 2018 NIBA meeting in New York, a conference for small-cap and micro-cap investors, providing an opportunity to present its recent developments. A video interview with CEO Warren Wang is currently available on NIBA’s website, during which Wang highlights CIIX’s future plans.  According to company data, NIBA’s members have cumulatively raised $15 billion in new capital for emerging growth companies, and the organization is responsible for 90 percent of all IPOs under $20 million.

Aiming to capitalize on rising interest in cryptocurrencies and their underlying blockchain technology, CIIX recently revealed that it plans to debut a new daily commentary show titled ‘Bitcoin Big Winner’ on the Phoenix North America Chinese Channel. The channel currently features 24/7 news, in-depth financial reports and live interviews highlighting the Chinese community throughout North America. It is available on major satellite, cable and IP television platforms (http://cnw.fm/9eO27).

CIIX is employing all forms of media to reach its audience about cryptocurrency news. It broadcasts ‘Bitcoin MultiMillionaire’, a daily video emanating from the New York Stock Exchange. The company also maintains a website, NewCoins168.com. Additionally, it hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters, and it recently purchased equipment to mine for cryptocurrencies, such as bitcoin and Litecoin, at a databank located near Seattle.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

• Infusion of Biotechnology Into Cannabis Market Leads to Booming Growth
• Medical Cannabis Payment Solutions’ (REFG) ‘Green’ is the Medical Cannabis Electronic Transaction Solution
• Global Payout, Inc. (GOHE) Financial Solutions Link World Companies of All Sizes

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$CHCI Announces Major Shift of Business Focus

WASHINGTON and RESTON, Va., April 02, 2018 — Comstock Holding Companies, Inc., (NASDAQ:CHCI) (“CHCI” or the “Company”), today announced it will be transitioning its business strategy and operating platform from for-sale homebuilding to commercial development, asset management and real estate services. Anchoring the transition is a long-term asset management agreement entered into by a wholly owned subsidiary of CHCI and privately held entities that own multiple mixed-use developments and stabilized assets at key Metro stations on Washington DC Metro’s Silver Line, which upon completion in 2020, will connect Dulles International Airport and Loudoun County to Tysons Corner and downtown Washington, DC. The assets under management (“AUM”) covered by the initial asset management agreement will at full build out include more than 5 million square feet of investment-grade, mixed-use assets encompassing more than 2,500 multi-family rental units, Class A and Trophy office, retail and entertainment buildings, hotels, and parking garages located adjacent to Silver Line Metro Stations; representing an estimated AUM value of $2.5 to $3.0 Billion.

Ownership of the portfolio of assets covered by the initial asset management agreement includes the Company’s Chairman/CEO and largest individual shareholder, Christopher Clemente, a prominent high net worth family office, and Daito Trust Construction, Ltd., one of the largest publicly traded Japanese developers and managers of multi-family assets.

The transition of the Company’s business platform represents the integration of the previously separate for-sale homebuilding operating platform of CHCI and the commercial development operating platform of Mr. Clemente’s private company into one public company: CHCI. The combination leverages the diverse capabilities and relationships developed over more than 30 years of Comstock’s commercial and residential development operations in the Washington, DC metropolitan area. The enhanced operating platform of CHCI will be service focused, transitioning from an on-balance sheet for-sale homebuilder into an asset manager of investment-grade commercial real estate assets and provider of real estate services operating through two real estate focused platforms:

• CDS Asset Management (“CAM”) will provide real estate development, asset management and property management services.
• Comstock Real Estate Services (“CRES”) will provide development supply chain services including capital markets, real estate brokerage, environmental consulting and design services.

“The shift from a for-sale homebuilding operation to a fee-for-service asset management model positions CHCI for greater financial stability, profitability and growth,” said Christopher Clemente, Chairman and Chief Executive Officer of CHCI.  “The transition will result in a substantial reduction in short-term and long-term debt; enhancing the overall financial profile of CHCI in the near term as we complete the majority of our for-sale homebuilding projects by year-end 2018, while also positioning CHCI to benefit from tremendous growth taking place in the Dulles Corridor of Fairfax County and Loudoun County.  With our initial asset management agreement in place, CHCI is positioned to expand AUM revenue through the development of multiple properties in markets experiencing high-demand for mixed-use, transit-oriented properties that have entitlements substantially in place, while pursuing additional growth in AUM and pursuing service based revenue growth through CRES.  We anticipate additional announcements in the coming months that will provide shareholders with additional details regarding our new business focus as well as visibility to the long-term growth prospects of CHCI.”

A detailed discussion of the Company’s strategic approach to creating value is covered in the Company’s latest investor relations presentation, which can be found at www.ComstockCompanies.com.

About Comstock Holding Companies, Inc.
CHCI is a multi-faceted real estate development, asset management and real estate related services company that, since 1985, has designed, developed, constructed and managed several thousand residential units and millions of square feet of residential and mixed-use projects throughout the Washington, DC metropolitan market and in other key markets in the southeastern United States. In early 2018, CHCI transitioned its operating platform from being primarily focused on developing on-balance sheet, for-sale, homebuilding projects to being focused on commercial real estate development, asset management and real estate related services. As a result, CHCI began operating through two real estate focused platforms, CDS Asset Management (“CAM”) and Comstock Real Estate Services (“CRES”). CAM provides real estate development, asset management, and property management services, while CRES provides development supply chain services, including capital markets, real estate brokerage, environmental consulting and design services in the Washington, DC metropolitan area and in New Jersey and Pennsylvania. Anchoring the transition of CHCI is a long-term asset management agreement covering two of the largest transit-oriented, mixed-use developments in the Washington, DC area; Reston Station, a 3 million square foot transit-oriented, mixed-use development located in Reston, VA, and Loudoun Station, a 2.5 million square foot transit-oriented, mixed-use development in Ashburn, VA, as well as other additional development assets. Comstock’s substantial experience in entitling, designing, developing, and managing a diverse range of properties including apartments, single-family homes, townhomes, mid-rise condominiums, high-rise condominiums and mixed-use (residential and commercial) properties, as well as large scale commercial parking garages and infrastructure projects, has positioned the Comstock organization as a premier developer and real estate related service provider in the mid-Atlantic Region. The Company is a publicly traded company, trading on NASDAQ under the symbol CHCI. For more information about CHCI or its businesses, please visit www.ComstockCompanies.com.

About Reston Station
Strategically located mid-way between Tysons Corner and Dulles International Airport, Reston Station is among the largest mixed-use, transit-oriented developments in the Washington, DC area. Located at the terminus of Phase I of Metro’s Silver Line, Reston Station is already home to more than 1,000 residents, numerous businesses, multiple retail establishments, and several restaurants. With more than 1 million square feet of completed and stabilized buildings, more than 2 million square feet of additional development in various stages of entitlement, development and construction, and a 3,500-space underground parking garage and transit facility adjacent to the Wiehle Reston-East Metro Station, the Reston Station neighborhood is taking shape and quickly becoming Fairfax County’s urban focal point in the Dulles Corridor. For more information about Reston Station, please visit; www.RestonStation.com

About Loudoun Station
Located at the terminus station on Metro’s Silver Line, minutes from Dulles International Airport, Loudoun Station represents Loudoun County’s first (and currently its only) Metro-connected development. Loudoun Station has approximately 700,000 square feet of mixed-use development completed, including hundreds of rental apartments, approximately 150,000 square feet of retail, restaurants, and entertainment venues, 50,000 square feet of Class-A office, and a 1,500-space commuter parking garage. More than 2 million square feet of additional development is slated for Loudoun Station.  Located adjacent to Metro’s Ashburn Station, the Loudoun Station neighborhood represents Loudoun County’s beginning transformation into a transit connected community with direct connectivity to Dulles International Airport, Reston, Tysons Corner and downtown Washington, DC. As Loudoun County’s only transit connected neighborhood, Loudoun Station has become the new downtown of Loudoun County in the Dulles Corridor. For more information about Loudoun Station, please visit; www.LoudounStation.com

Cautionary Statement Regarding Forward-Looking Statements
This release includes “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by use of words such as “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” “will,” “should,” “seeks” or other similar expressions. Forward-looking statements are based largely on our expectations and involve inherent risks and uncertainties, many of which are beyond our control. You should not place undue reliance on any forward-looking statement, which speaks only as of the date made. Some factors which may affect the accuracy of the forward-looking statements apply generally to the real estate industry, while other factors apply directly to us. Any number of important factors which could cause actual results to differ materially from those in the forward-looking statements include, without limitation: our ability to successfully transition our business platform, including the winding down of our homebuilding business and our performance under the asset management agreement; completion of Comstock’s financial accounting and review procedures; general economic and market conditions, including interest rate levels; our ability to service our debt; inherent risks in investment in real estate; our ability to compete in the markets in which we operate; economic risks in the markets in which we operate, including actions related to government spending; delays in governmental approvals and/or land development activity at our projects; regulatory actions; fluctuations in operating results; our anticipated growth strategies; shortages and increased costs of labor or building materials; the availability and cost of land in desirable areas; adverse weather conditions or natural disasters; our ability to raise debt and equity capital and grow our operations on a profitable basis; and our continuing relationships with affiliates. Additional information concerning these and other important risk and uncertainties can be found under the heading “Risk Factors” in our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, for the fiscal year ended December 31, 2017. Our actual results could differ materially from these projected or suggested by the forward-looking statements. Comstock claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements contained herein. Comstock specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Company:
Comstock Holding Companies, Inc.
Christopher Conover, 703-230-1985
Chief Financial Officer: Christopher Conover
Source: Comstock Holding Companies, Inc.

$SLS Positive Interim Data, Phase 2b NeuVax Clinical in Breast Cancer

Clinically meaningful activity in favor of investigational nelipepimut-S (NeuVax) + Herceptin arm

Clinically and statistically significant efficacy in triple negative breast cancer (TNBC) cohort; p=0.023

NEW YORK, April 02, 2018 — SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin®) +/- nelipepimut-S (NeuVax™)  in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences.

A pre-specified interim analysis, conducted by an independent Data Safety Monitoring Board (DSMB) of the efficacy and safety data for the study in an overall population of 275 patients as well as the two primary study target patient populations (node-positive and TNBC) after a median follow-up of 19 months,  demonstrated a clinically meaningful difference in median disease-free survival (DFS) in favor of the active arm (NeuVax + Herceptin), a primary endpoint of the study, with hazard ratios of 0.67 and 0.61 in the intent to treat (ITT) and modified ITT (mITT) populations (i.e., those who received at least one dose of vaccine or control) as well as a 34.9% and 39.5% reduction in relative risk of recurrence in the active versus control arms in the ITT and mITT populations, respectively.

A clinically meaningful and also statistically significant difference was found between the two arms in the cohort of patients (n= 98) with triple-negative breast cancer (TNBC), with a hazard ratio of 0.26 and a p-value of 0.023 in favor of the NeuVax + Herceptin combination with a 70.4% reduction in relative risk of recurrence in the active arm versus control.  Similarly, a clinically meaningful and statistically significant difference was found between the two arms in favor of the combination in the cohort of patients not receiving hormonal therapy (n = 110), with a hazard ratio of 0.24 and a p-value of 0.009 with a 74.1% reduction in relative risk of recurrence in the active arm versus control. This pre-specified interim analysis also showed an adverse event profile with no notable differences between treatment arms.  The addition of NeuVax to Herceptin did not result in any additional cardiotoxicity compared to Herceptin alone.

“We are indeed excited about these compelling results and believe NeuVax + Herceptin has the potential to become an important therapeutic option for TNBC patients.  The positive NeuVax phase 2b data underscores the innovative science and approach we have taken to investigate this agent’s potential to address this persistent therapeutic challenge.  We plan to immediately engage with the FDA and EMA, as per the recommendation of the DSMB, to identify the optimal path forward in this particular patient group, while advancing the drug through a partnership or other strategic collaboration,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “These are indeed unique and exciting clinical data for TNBC patients, and I would like to extend my sincere gratitude to all patients who have participated in this clinical trial, as well as the study teams.”

The NeuVax + Herceptin combination was found to be generally well-tolerated. The majority of treatment-emergent adverse events (TEAE) were of mild or moderate (G1/G2) severity and the majority of G3 systemic TEAEs were unrelated to NeuVax.  Treatment-related adverse events consisted primarily of manageable local injection site reactions, skin induration, pruritus and fatigue.

Additionally, in the NeuVax + Herceptin arm, in vivo HER2-specific T-cell immune responses (IRs), assessed by delayed type hypersensitivity (DTH) skin testing, showed a time-dependent increase in IR potency compared to the earliest tested datapoint (p=0.000023), while no such increase was observed in the control arm.

Based on the results above, the DSMB has recommended to expeditiously seek regulatory guidance by the FDA for further development of the combination of NeuVax + Herceptin in TNBC, considering the statistically significant benefit of the combination therapy seen in this population with large unmet medical need.

“We are very pleased with these findings, which suggest that NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low-to-intermediate HER2-expression, especially given the recent report of the NSABP B-47 trial showing no benefit in these patients with Herceptin alone.  Furthermore, our trial has shown a significantly improved disease-free survival in women with TNBC.  The favorable findings for this cohort are particularly promising, given the limited treatment options for these patients with high risk of recurrence and death,” commented COL (ret) George E. Peoples, MD, FACS, the study director and sponsor-investigator of the IST. “We look forward to presenting these data at an upcoming major medical conference and to supporting SELLAS in the regulatory and developmental pathway for NeuVax.”

Herceptin^® is a registered trademark of Genentech, Inc. and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.

About the NeuVax + Herceptin study

This Phase 2b trial is a multi-center, randomized, single-blinded, placebo-controlled trial in 275 HER2 1+/2+ breast cancer patients with positive nodes and/or TNBC. The study combines NeuVax and trastuzumab (Herceptin) in the adjuvant setting aiming to prevent recurrence or death. Tumors in these women show low levels of expression of HER2, as measured by immunohistochemistry (IHC), i.e., at a level of either 1+ or 2+ and, hence, these patients are not considered candidates for Herceptin. Patients who are hormone receptor-negative and HER2 1+/2+ by IHC are currently defined as ‘triple-negative’ breast cancer (TNBC) patients. NeuVax (nelipepimut-S) is a potentially first-in-class, HER2-directed cancer immunotherapy and is the immunodominant peptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. The nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTLs) following binding to specific HLA molecules on antigen presenting cells (APC) and destroy HER2 expressing cancer cells.

About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types.  GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications.  SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesothelioma (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer.  SELLAS plans to study GPS in up to four additional indications.  SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the results of clinical studies and as to further development of nelipepimut-S (NeuVax) for breast cancer. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with immune-oncology product development and clinical success thereof, uncertainties related to timing and ability to obtain needed shareholder consent in a timely manner, the uncertainty of regulatory approval, the uncertainty of partnering its clinical assets, and other risks and uncertainties affecting SELLAS and its development programs. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
ir@sellaslife.com

David Moser, JD
SELLAS Life Sciences Group, Inc.
813-864-2571
info@sellaslife.com

$NETE Aims to Transform the Online and Mobile Payments Experience

April 2, 2018

• Point-of-sale terminals market expected to reach $116 billion by 2025 with a CAGR of 9.9 percent
• Appointment of seasoned fintech specialists to board of directors brings valuable domestic, international finance expertise to company
• Mobile commerce projected to account for 70 percent of ecommerce sales in China and India, while at least one-third of retail sales in the U.K., Germany and the U.S. will stem from ecommerce

Global technology and value-added solutions company Net Element, Inc. (NASDAQ: NETE) has thrived on developing innovative ideas into marketable solutions that engage users in various segments of the highly competitive global ecommerce marketplace (http://nnw.fm/3eKay). Value-added transactional innovations such as Aptito, an all-in-one iOS cloud-based restaurant management and payment acceptance solution, along with ecommerce and retail payment transaction and processing brands such as PayOnline and Unified Payments, add convenience and alternatives to cash payments for retail transactions.

A surge in demand for wireless technologies and the rise of ecommerce is expected to drive the overall global point-of-sale terminals market to a whopping $116 billion by 2025, according to Grand View Research (http://nnw.fm/immR6). An article in Entrepreneur notes that there are numerous advantages underpinning the transition from a society that favors plastic bankcards to a marketplace that allows consumers to pay through their mobile devices (http://nnw.fm/E3Quf). Chief among these are ease of transactions, greater security and heightened convenience. In addition, mobile payments can be a real timesaver, which makes them seriously attractive for millennials (http://nnw.fm/0lF0c).

In a news release, Jonathan Fichman, the newest member of Net Element’s board of directors (http://nnw.fm/zXzm9), said, “The company’s recently announced plans to create a blockchain payments platform and its recently released next generation cloud-based point of sale payments system will both be impactful innovations for the industry.”

Fichman, whose 20-plus years of strategic domestic and international finance expertise within Fortune 100 companies includes extensive experience in fintech, payments, blockchain, wealth management and banking, joins Jon ‘Dr. J’ Najarian, who was also recently appointed to the board. Najarian, a professional investor, money manager and media analyst, is also a CNBC personality (regularly appearing on the ‘Halftime Report’ and ‘Fast Money’ programs) (http://nnw.fm/yKW6i) and a former linebacker for the Chicago Bears.

The global ecommerce market reached $2.3 trillion in 2017, and it’s expected to soar to a ‘mind-boggling’ $4.5 trillion by 2021, according to a Statista report (http://nnw.fm/lg9tK). Another industry perspective notes that mobile commerce will account for more than 70 percent of ecommerce sales in both China and India in 2017, with mobile commerce accounting for a full third of total retail ecommerce sales in the U.K., Germany, and the U.S (http://nnw.fm/8IdUS).

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes, applying multi-channel platforms, all-in-one digital solutions and end-to-end encryption of cardholder data that utilizes tamper-resistant hardware to ensure integrity and simplify security. Net Element was ranked number 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies.

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

• SmartCash ($SMART) and the Future Potential of SmartCard
• First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) Announces Positive Cobalt Mineralization in Assay Core Samples
• IEG Holdings Corp. (IEGH) Delivering Loan Assistance to Underbanked Market

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CIIX To Capitalize on Growing Demand for CBD-based Health Products

March 5, 2018

• CIIX announces spinoff of all hemp-related assets into a single private company
• CIIX shifts primary focus to core financial services, including cryptocurrency and blockchain technology

ChineseInvestors.com, Inc. (OTCQB: CIIX) has become the premier financial information website providing real-time market commentary, analysis and education-related services to Chinese-speaking investors. In 2018, the company is strategically focusing on building its core financial services business. CIIX has announced a spinoff of all hemp-related assets as the company explores new ways to expand.

CIIX announced plans to spin off all hemp-related assets into a single private company. CBD Biotechnology Co. Ltd., ChineseHempOil.com, Inc. and Hemp Logic Inc. will be combined into a single private company. Shareholders have the opportunity to take advantage of this dividend. CIIX CEO Warren Wang is encouraging holders of CIIX preferred stock to convert into common before May 31, 2018, the date of the spinoff.

The subsidiaries are well positioned to achieve significant growth. This spinoff is part of the groundwork to capitalize on the growing demand for CBD-based nutrition and health products in the U.S. and China. In January, these subsidiaries made a combined $100,000. The progress of the newly formed company will be overseen by CIIX, but the spinoff of CBD-focused assets will allow CIIX to focus on core financial services, including cryptocurrency and blockchain technology.

Since 1999, CIIX has been leading the way in providing financial information and education for Chinese-speaking investors. With the formation of the new company, CIIX plans to focus on its new cryptocurrency division and core financial education business, including ‘Bitcoin MultiMillionaire’, a daily newscast broadcast by CIIX as a free bitcoin education site in the Chinese language. The broadcast was launched in recognition of the growing interest in cryptocurrency among Chinese investors. CIIX provides reliable market information to help investors make informed decisions to meet their personal financial goals.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

• Medical Cannabis Payment Solutions’ (REFG) ‘Green’ is the Medical Cannabis Electronic Transaction Solution
• Global Payout, Inc. (GOHE) Financial Solutions Link World Companies of All Sizes
• Marijuana Company of America, Inc. (MCOA) Leading the Way in the Cannabis and Hemp Industry

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$SENS Favorable Outcome of FDA Advisory Committee on Eversense

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced a favorable outcome of the U.S. Food and Drug Administration (FDA) Clinical Chemistry and Clinical Toxicology Devices meeting on the Eversense system. The panel, comprised of independent medical experts, voted unanimously, 8 to 0, that the benefits outweigh the risks, voted unanimously, 8 to 0, that the system is safe, and voted unanimously, 8 to 0, that the system is effective.

“We are pleased that the advisory panel believes in the benefits of the Eversense system. We are confident that the benefits of the system – longest life sensor, sustained accuracy, predictive glucose alerts, removable smart transmitter, gentle-on-skin adhesive – can be life changing for people with diabetes, and this is another step toward offering these benefits to patients in the U.S.,” stated Tim Goodnow, President and Chief Executive Officer of Senseonics. “We thank the panel members, the participants in today’s meeting, the clinical trial participants and the FDA, and are eager to continue the positive dialogue with FDA in pursuit of approval for Eversense.”

The Eversense system is a first of its kind implantable continuous glucose monitoring system utilizing a sensor that lasts for up to 90 days. The company demonstrated safety, efficacy and a favorable risk benefit profile for Eversense through real world data from patients currently using the system in Europe and data from the U.S. PRECISE II study. The study is considered one of the largest studies of a CGM system in the world, including over 2 million sensor glucose readings, from 90 participants at eight clinical centers.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements about the timing of FDA review and the potential U.S. launch of Eversense and other statements containing the words “expect,” “intend,” “may,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to the recommendation of the panel with respect to the PMA, the ultimate decision by the FDA with respect to the PMA, timing of any such decision and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2017, and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

Senseonics Holdings, Inc.
Investor Contact
R. Don Elsey
Chief Financial Officer
301-556-1602
don.elsey@senseonics.com

$AKG to Receive US$185 Million From Gold Fields for 50% Joint Venture

VANCOUVER, British Columbia, March 29, 2018 — Asanko Gold Inc. (“Asanko” or the “Company”) (TSX:AKG) (NYSE American:AKG) is pleased to announce that it has entered into certain definitive agreements under which Asanko will receive US$185 million for a 50% joint venture (“JV”) interest in its Asanko Gold Mine (“AGM”) from subsidiaries of Gold Fields Limited (“Gold Fields”) (JSE:GFI) (NYSE:GFI), one of the world’s largest gold producers and the second largest gold producer in Ghana.

Under the various transaction agreements (“Transactions”), Asanko and Gold Fields will, among other things, form an incorporated 50:50 corporate JV which will own Asanko’s 90% interest in the Asanko Gold Mine (the “AGM”) and all associated properties in Ghana. The Government of Ghana will continue to hold a free-carried 10% interest. In addition to the JV interest, Gold Fields will purchase a 9.9% shareholding interest in Asanko for approximately US$17.6 million to purchase 22,354,657 shares at approximately US$0.79, equal to the 5-day VWAP as of market close on March 27, 2018. Asanko will host an investor conference call at 9am ET today, details below.

Transaction Highlights

• Asanko will receive from Gold Fields:
  • US$165 million in cash, payable upon closing of the JV Transaction expected before end of Q3 2018
  • US$20 million in cash, also payable for the JV Transaction, on an agreed Esaase development milestone but in any event no later than December 31, 2019
  • US$17.6 million from Gold Fields for a 9.9% private placement in Asanko shares at a price of US$0.79 anticipated to be completed in the immediate future
• Asanko will remain the manager and  operator of the AGM and will continue to be paid an arm’s length management fee for services rendered to the JV of approximately US$6 million per annum
• Asanko will use the proceeds primarily to repay its outstanding Red Kite debt of US$164 million
• Asanko views the JV as a significantly superior outcome than a restructuring of the Red Kite debt facility as it provides a balanced risk/return profile and creates a debt free platform that will enable Asanko to accelerate growth opportunities and pursue its strategy of becoming a mid-tier gold producer

“This transaction presents a unique opportunity for Asanko to de-risk its future production targets whilst at the same time eliminating corporate debt. With a healthy balance sheet and robust operational cash flows, together with a strong technical endorsement, our Life of Mine plan is assured,” said Asanko President and CEO, Peter Breese.

“After carefully weighing the benefits of this transaction, we have determined that it is superior to the alternative of engaging with Red Kite to extend our debt. With the repayment of the Red Kite debt, Asanko has achieved significant financial flexibility moving forward as we seek to continue to grow our business over the medium term.”

“The mine is now operating well within our business targets, with mining efficiencies and the process plant delivering ahead of plan. With this new investment and the freeing up of our balance sheet, we will now move forward with the development of our large scale Esaase deposit, with a view to commencing production in 2019 with an interim trucking operation until the conveyor is fully operational in late 2020. We look forward to working in partnership with Gold Fields and sharing mining and exploration expertise to create added value for all our stakeholders.”

Nicholas Holland, CEO of Gold Fields, commented: “West Africa is an important part of our business and we look forward to a long partnership with Asanko in Ghana. We view the Asanko Gold Mine as a high quality asset and a great addition to our existing portfolio of open pit gold operations in the country.”

Transaction Rationale

• Significantly improved balance sheet
  • Asanko emerges debt free following repayment of Red Kite Facility
  • Strong attributable pro forma cash position of approximately US$35 million (US$55 million including deferred consideration) as at March 23, 2018
• World-Class Partner with Experience in Ghana
  • Gold Fields is Ghana’s second largest gold producer with more than 20 years of in-country experience
  • Gold Fields brings considerable technical and exploration expertise that complements Asanko’s existing development and operating capabilities
• Management and Asset Validation
  • Partnership endorses Gold Fields confidence in Asanko’s mine operator capabilities
  • Partnership validates the AGM from a technical and operational perspective
• Well Positioned for Future Growth
  • Near-term organic growth self funded by the AGM from internally generated cash flows
  • Robust balance sheet with which to fund growth initiatives

Further Transaction Particulars
Under the terms of the Transaction, on closing, Gold Fields will acquire a 50% participating interest in Asanko’s 90% ownership interest in the AGM for an aggregate US$185 million in cash, of which US$165 million is payable upon closing. The remaining US$20 million is payable upon achievement of an agreed Esaase development milestone but in any event by no later than December 31, 2019.

The closing of the Transaction is expected to occur before end of Q3 2018 and is subject to customary conditions precedent including that no material adverse event occurs and Ghanaian Minister of Lands and Natural Resources does not object.

The Transaction will impact the recognition, presentation and measurement of assets and liabilities associated with the Company’s Ghanaian operations. The results of which are expected to result in a non cash impairment charge based on the JV Transaction indicative asset value.

The Joint Venture Agreement
Asanko will remain the manager (operator) of the AGM. A management committee will be formed, with representatives from each party, to govern the operating and development activities of JV. The JV will continue to pay Asanko an arm’s length management fee for services rendered of approximately US$6 million per annum. The JV will fund its growth from operating cash flow. The JV Agreement has customary terms for program participation elections, dilution of equity interest for non-participation, sole risk rights for new projects and expedited dispute resolution.

The Private Placement and Investor Rights Agreement
Gold Fields has agreed to purchase 22,354,657 common shares of the Company through a private placement, at a price of approximately US$0.79 per share (the “Private Placement”) equal to the 5-day VWAP as of market close on March 27, 2018. The net proceeds of the Private Placement will total approximately US$17.6 million, which will further strengthen Asanko’s balance sheet. These shares are subject to a customary four month resale restricted period in Canada. In connection with the Private Placement, Gold Fields will sign an investor rights agreement with Asanko under which Gold Fields will receive certain rights to participate in future Asanko share issuances in order to maintain its 9.9% shareholding for up to five years. In addition, Gold Fields has agreed that it will standstill at this level of ownership for a one year period unless Asanko otherwise consents, and will support Asanko management nominees at shareholder meetings. The Private Placement is anticipated to be completed in the immediate future and has received conditional TSX approval.

Repayment of the Red Kite Debt
Asanko will use the JV Transaction cash to repay in full all outstanding principal and accrued interest (US$164 million) owing to RK Mine Finance Trust I (“Red Kite”) under the Definitive Senior Facilities Agreement upon closing. There are no early repayment penalties associated with the Red Kite debt. Red Kite’s current gold offtake agreement will remain in effect until all outstanding ounces have been delivered to Red Kite or the JV elects to terminate the offtake and pay the associated fee.

In the event that the JV Transaction has not completed by July 1, 2018, when the first principal repayment of the Red Kite debt is due, Gold Fields has also agreed to provide a bridge loan of up to US$20 million for Asanko, to be drawn at Asanko’s sole discretion. The bridge loan will be credited towards Gold Fields’ contribution to the Joint Venture on closing.  If closing does not complete for any reason, the bridge loan will be repayable, after written demand with a 30 day notice, at any time after six months from the date of advance of the bridge loan. If Asanko does not repay the bridge loan, the bridge loan claim would effectively be used to subscribe for new common shares of Asanko, up to the point where Gold Fields would own 19.9% of the outstanding Asanko shares, and the balance would be repaid in cash. Pricing of these shares is subject to TSX policy.

Development of Esaase Proceeding
The development of the large-scale Esaase deposit will commence in 2018 and initial production is expected in Q1 2019 with an interim trucking operation of approximately 1.5 million tonnes per annum during 2019 and 2020. The pre-production capital associated with opening up Esaase is approximately US$9 million, of which US$7 million is expected to be spent in 2018. A trucking permit has been applied for and is anticipated before the end of 2018.

2018 Guidance and 5 Year Outlook
As announced on March 15, 2018, the Company released its 2018 Guidance and 5-Year Outlook, which is summarized below. This Transaction will enable the AGM to generate strong cash flows to fund its capital requirements over the next three years.

Notes: Based on US$1,250/oz gold and construction of the overland conveyor in 2019/20 

Advisors
In connection with this transaction, BMO Capital Markets and Taurum International acted as financial advisors and McMillan LLP acted as legal counsel to Asanko. Fasken Martineau DuMoulin LLP acted as legal counsel to Gold Fields.

Notes:
¹ Non-GAAP Performance Measures
The Company has included certain non-GAAP performance measures in this press release, including all-in sustaining costs per gold ounce (“AISC”). These non-GAAP performance measures do not have any standardized meaning. Accordingly, these performance measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

The Company has adopted the World Gold Council’s guidance for reporting of AISC. AISC include total cash costs, corporate overhead expenses, sustaining capital expenditure, capitalized stripping costs and reclamation cost accretion for each ounce of gold sold.

Qualified Persons
Frederik Fourie, Asanko Senior Mining Engineer (Pr.Eng.) is the Asanko Qualified Person, as defined by Canadian National Instrument 43-101 (Standards of Mineral Disclosure), who has approved the preparation of the mining technical contents of this news release.

About Asanko Gold Inc.
Asanko’s vision is to become a mid-tier gold mining company that maximizes value for all its stakeholders. The Company’s flagship project is the multi-million ounce Asanko Gold Mine located in Ghana, West Africa. Asanko is managed by highly skilled and successful technical, operational and financial professionals. The Company is strongly committed to the highest standards for environmental management, social responsibility, and health and safety for its employees and neighbouring communities.

About Gold Fields Limited
Gold Fields Limited is a globally diversified gold producer with seven operating mines in Australia, Ghana, Peru and South Africa, and a total attributable annual gold-equivalent production of approximately 2.2 million ounces. It has attributable gold Mineral Reserves of around 49 million ounces and gold Mineral Resources of around 104 million ounces. Attributable copper Mineral Reserves total 764 million pounds and Mineral Resources 4,881 million pounds. Gold Fields has a primary listing on the Johannesburg Stock Exchange (JSE) Limited, with secondary listings on the New York Stock Exchange (NYSE) and the Swiss Exchange (SIX).

Forward-Looking and other Cautionary Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address the completion of announced agreements including the agreement with Gold Fields, estimated resource quantities, grades and contained metals, possible future mining, exploration and development activities, are forward-looking statements. Although the Company believes the forward-looking statements are based on reasonable assumptions, such statements should not be in any way construed as guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices for metals, the conclusions of detailed feasibility and technical analyses, the timely renewal of key permits, lower than expected grades and quantities of resources, mining rates and recovery rates and the lack of availability of necessary capital, which may not be available to the Company on terms acceptable to it or at all. The Company is subject to the specific risks inherent in the mining business as well as general economic and business conditions. For more information on the Company, Investors should review the Company’s Annual Form 40-F filing with the United States Securities Commission and its home jurisdiction filings that are available at www.sedar.com.

Neither Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note to US Investors Regarding Mineral Reporting Standards:
Asanko has prepared its disclosure in accordance with the requirements of securities laws in effect in Canada, which differ from the requirements of US securities laws. Terms relating to mineral resources in this press release are defined in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects under the guidelines set out in the Canadian Institute of Mining, Metallurgy, and Petroleum Standards on Mineral Resources and Mineral Reserves. The Securities and Exchange Commission (the “SEC”) permits mining companies, in their filings with the SEC, to disclose only those mineral deposits that a company can economically and legally extract or produce. Asanko uses certain terms, such as, “measured mineral resources”, “indicated mineral resources”, “inferred mineral resources” and “probable mineral reserves”, that the SEC does not recognize (these terms may be used in this press release and are included in the public filings of Asanko which have been filed with securities commissions or similar authorities in Canada).

Enquiries:
For further information please visit: www.asanko.com, email: info@asanko.com or contact:

Alex Buck - Manager, Investor and Media Relations
Toll-Free (N.America): 1-855-246-7341
Telephone: +44-7932-740-452
Email: alex.buck@asanko.com

Rob Slater – Executive, Corporate Development and Strategy
Telephone: +27-11-467-2758
Email: rob.slater@asanko.com

$NETE Recent Analysis, Renewed Outlook, Key Drivers of Growth

NEW YORK, March 29, 2018 — In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Net Element, Inc. (NASDAQ:NETE), McGrath RentCorp (NASDAQ:MGRC), AvalonBay Communities, Inc. (NYSE:AVB), American Tower Corporation (REIT) (NYSE:AMT), Earthstone Energy, Inc. (NYSE:ESTE), and Macerich Company (NYSE:MAC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

NETE DOWNLOAD: http://Fundamental-Markets.com/register/?so=NETE
MGRC DOWNLOAD: http://Fundamental-Markets.com/register/?so=MGRC
AVB DOWNLOAD: http://Fundamental-Markets.com/register/?so=AVB
AMT DOWNLOAD: http://Fundamental-Markets.com/register/?so=AMT
ESTE DOWNLOAD: http://Fundamental-Markets.com/register/?so=ESTE
MAC DOWNLOAD: http://Fundamental-Markets.com/register/?so=MAC

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Net Element, Inc. (NASDAQ:NETE), McGrath RentCorp (NASDAQ:MGRC), AvalonBay Communities, Inc. (NYSE:AVB), American Tower Corporation (REIT) (NYSE:AMT), Earthstone Energy, Inc. (NYSE:ESTE), and Macerich Company (NYSE:MAC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

—————————————–

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 27th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

—————————————–

NET ELEMENT, INC. (NETE) REPORT OVERVIEW

Net Element’s Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Net Element reported revenue of $14.90MM vs $14.01MM (up 6.36%) and basic earnings per share -$0.90 vs -$2.47. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Net Element reported revenue of $54.29MM vs $40.24MM (up 34.92%) and basic earnings per share -$10.33 vs -$23.22. Net Element is expected to report earnings on April 6th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.10.

To read the full Net Element, Inc. (NETE) report, download it here: http://Fundamental-Markets.com/register/?so=NETE

—————————————–

MCGRATH RENTCORP (MGRC) REPORT OVERVIEW

McGrath RentCorp’s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, McGrath RentCorp reported revenue of $122.23MM vs $105.28MM (up 16.09%) and basic earnings per share $4.90 vs $0.40 (up 1,125.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, McGrath RentCorp reported revenue of $462.03MM vs $424.08MM (up 8.95%) and basic earnings per share $6.41 vs $1.60 (up 300.63%). McGrath RentCorp is expected to report earnings on May 1st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $2.91 and is expected to report on February 26th, 2019.

To read the full McGrath RentCorp (MGRC) report, download it here: http://Fundamental-Markets.com/register/?so=MGRC

—————————————–

AVALONBAY COMMUNITIES, INC. (AVB) REPORT OVERVIEW

AvalonBay Communities’ Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, AvalonBay Communities reported revenue of $555.29MM vs $518.24MM (up 7.15%) and basic earnings per share $1.71 vs $1.76 (down 2.84%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, AvalonBay Communities reported revenue of $2,158.63MM vs $2,045.26MM (up 5.54%) and basic earnings per share $6.36 vs $7.53 (down 15.54%). AvalonBay Communities is expected to report earnings on April 25th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $2.09. The estimated EPS forecast for the next fiscal year is $9.32 and is expected to report on January 30th, 2019.

To read the full AvalonBay Communities, Inc. (AVB) report, download it here: http://Fundamental-Markets.com/register/?so=AVB

—————————————–

AMERICAN TOWER CORPORATION (REIT) (AMT) REPORT OVERVIEW

American Tower Corporation (REIT)’s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, American Tower Corporation (REIT) reported revenue of $1,704.46MM vs $1,539.58MM (up 10.71%) and basic earnings per share $0.50 vs $0.47 (up 6.38%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, American Tower Corporation (REIT) reported revenue of $6,663.90MM vs $5,785.70MM (up 15.18%) and basic earnings per share $2.69 vs $2.00 (up 34.50%). American Tower Corporation (REIT) is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $1.58. The estimated EPS forecast for the next fiscal year is $8.01 and is expected to report on February 26th, 2019.

To read the full American Tower Corporation (REIT) (AMT) report, download it here: http://Fundamental-Markets.com/register/?so=AMT

—————————————–

EARTHSTONE ENERGY, INC. (ESTE) REPORT OVERVIEW

Earthstone Energy’s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Earthstone Energy reported revenue of $35.68MM vs $15.15MM (up 135.45%) and basic earnings per share $0.12 vs -$1.60. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Earthstone Energy reported revenue of $108.08MM vs $42.27MM (up 155.69%) and basic earnings per share -$0.53 vs -$2.92. Earthstone Energy is expected to report earnings on May 14th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.06. The estimated EPS forecast for the next fiscal year is $1.16 and is expected to report on March 13th, 2019.

To read the full Earthstone Energy, Inc. (ESTE) report, download it here: http://Fundamental-Markets.com/register/?so=ESTE

—————————————–

MACERICH COMPANY (MAC) REPORT OVERVIEW

Macerich’s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Macerich reported revenue of $256.74MM vs $272.00MM (down 5.61%) and basic earnings per share $0.23 vs $0.35 (down 34.29%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Macerich reported revenue of $993.66MM vs $1,041.27MM (down 4.57%) and basic earnings per share $1.02 vs $3.52 (down 71.02%). Macerich is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.87. The estimated EPS forecast for the next fiscal year is $4.15 and is expected to report on February 4th, 2019.

To read the full Macerich Company (MAC) report, download it here: http://Fundamental-Markets.com/register/?so=MAC

—————————————–

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers (“Registered Members”) working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

$PBIO to Discuss Fourth Quarter and FY2017 Financial Results

SOUTH EASTON, MA / March 29, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2017 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company’s website approximately one day after the teleconference).

The teleconference will include a Company presentation followed by a question & answer period.

Date: Tuesday, April 3, 2018 Time: 4:30 PM Eastern Daylight Time (EDT)

To attend this teleconference live by telephone:

Dial-in: (877) 407-8031 (North America); (201) 689-8031 (International)

Verbal Passcode (for the operator): PBI Fourth Quarter and FY2017 Financial Call & Business Update

For those unable to participate in the live teleconference, a replay will be available beginning Wednesday, April 4, 2018. The replay will be accessible via telephone and the Company’s website for 30 days.

Replay Number: (877) 481-4010 (North America); (919) 882-2331 (Int’l); Replay ID Number: 27377

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

For more information about PBI and this press release, please click on the following link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President & CEO (T) 508-230-1828

$CHOOF Countdown to Canada’s Recreational Cannabis Industry Enters Retail Territory

March 29, 2018

NetworkNewsWire Editorial Coverage: Recreational cannabis will soon be legal in Canada for adults, but selling and buying the pungent herb won’t be as simple as some presume it will be. Regulations governing the cultivation, production, packaging and sale of cannabis are still being refined as Canadian lawmakers at different levels of government tackle unique differences between provinces and local jurisdictions. One thing is certain, however: a cannabis retail explosion is coming, and cannabis companies ready for the surge will reap the benefits when Canada’s recreational marketplace officially opens for business. Cannabis retail brand Choom™ Holdings, Inc. (CSE: CHOO) (OTCQB: CHOOF) (CHOOF Profile) is preparing to meet the demands of this market with a strategic blend of product and consumer experience, while Hiku Brands Company. Ltd. (CSE: HIKU) (OTC: DJACF) (DJACF Profile) steadies itself as a lifestyle cannabis brand. Canada’s top cultivators, Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF); Aurora Cannabis, Inc. (TSX: ACB) (OTCQX: ACBFF); and ABcann Global (TSX-V: ABCN) (OTCQB: ABCCF) (ABCCF Profile) are also exploring getting in the game.

Economic Boost

Close to 5 million Canadians aged 15 to 64 spent an estimated $5.7 billion on cannabis in 2017, according to a Cannabis Economic Account issued by Statistics Canada (http://nnw.fm/m1AnR). That’s nearly $1,200 per cannabis consumer, although the report does caution that the data is an estimate. Canada’s foray into legalized recreation cannabis will bring more concrete numbers, especially once the nation’s projected $450 million in annual cannabis tax revenue begins to roll in, and the nation’s provinces get a 75 percent share of the loot (http://nnw.fm/EhMe6).

Retail Me Now

Estimates vary as to how much revenue is out there when it comes to legalized cannabis. A 2016 report (http://nnw.fm/R5Csq) from the Canadian Parliamentary Budget Officer estimated a $5.5 billion to $5.8 billion annual retail market while a far more enthusiastic Deloitte study predicted an industry generating more than $22 billion a year (http://nnw.fm/dR0OF). Either way, that translates into an undeniable demand for cannabis. For Choom Holdings (CSE: CHOO) (OTCQB: CHOOF) and its experienced team of cannabis curators, Canada’s upcoming “green rush” presents an incredible opportunity to build premium brand loyalty through the company’s unique retail strategy.

Cannabis Connoisseur

A heady amount of the laid-back spirit of Hawaii is channeled into Choom™ and its unofficial history. Choom was inspired by the Choom Gang, a group of buddies living in Honolulu during the 1970s who loved to relax with “choom,” the local’s term for marijuana. That Choom “vibe” flows throughout the corporate structure today with the company’s commitment to the principle of keeping and maintaining “good times and good friends.”

One of the best ways to do that may be by cultivating naturally grown, premium cannabis that provides an elevated experience for the consumer, then sharing that business model with entrepreneurs in a unique Choom Partner Program (http://nnw.fm/gYs2q). This chain of branded retail cannabis dispensaries will find homes in Canadian jurisdictions where recreational cannabis is legalized for retail sale.

License to Sell

The government in British Columbia, where Choom is headquartered, has issued several guidelines for individuals and businesses seeking a recreational cannabis retail license. Importantly, while the government said the B.C. Liquor Distribution Branch would be the wholesale distributor of nonmedical cannabis, it would not impose a quota on the number of licenses issued for private retail outlets (http://nnw.fm/4PKfP). That’s good news for individuals and companies seeking an entry into the booming cannabis sector.

Fittingly, Choom recently announced it has signed the first agreement in its retail investor program with a consortium known as the Thompson Okanagan Choom Group. Comprised of local investors and business partners, the consortium has secured the exclusive territory rights to open multiple Choom-branded retail dispensaries in the gorgeous Thompson-Okanagan region of British Columbia (http://nnw.fm/4kJMd).

Each Choom retail store is designed with a clean and modern mindset geared to help customers feel at home and enjoy the “aloha” experience. The company’s partner program includes support and access to the expertise and partnerships of the Choom brand and its nimble, adaptive business model. As experienced curators of cannabis, Choom will use its products and services to grow and adapt to the changing cannabis landscape, which is likely a necessary component in Canada’s current regulatory climate.

But Wait, There’s More

While it appears the distribution of wholesale cannabis and online sales will be largely government controlled, provinces and territories have opted for one of three retail models for over-the-counter sales: private, public or a hybrid of the two (http://nnw.fm/Nij0p). The Saskatchewan government, for instance, announced in January that the Saskatchewan Liquor and Gaming Authority would be tasked with issuing about 60 retail permits to private stores located in roughly 40 municipalities and First Nations across the province (http://nnw.fm/w4fCh). Ontario, on the other hand, will only allow cannabis to be sold by the Ontario Cannabis Retail Corporation, a subsidiary of the Liquor Control Board of Ontario (http://nnw.fm/qyg7E).

Cultivating an Experience

Choom has acquired International Tungsten, Inc. (ITI), a late-stage applicant for an ACMPR (Access to Cannabis for Medical Purposes Regulations) cultivation license through its subsidiary, Specialty Medijuana Products Inc. (SMP) (http://nnw.fm/p2Tax). SMP, whose cultivation facility is located in British Columbia, expects to receive its Health Canada cultivation license within the next few weeks, followed by a sales license by the third quarter of 2018. Benefits of this acquisition are significant, moving Choom closer to scaling up cultivation capacity and reaping its first cannabis harvest under this new resource (http://nnw.fm/5A3qi).

Choom already has security clearance with one ACMPR through its subsidiary Medi-CanHealth Solutions Ltd., which is currently in the detailed review stage. Growth plans include a Phase 1 cannabis production facility capable of producing approximately 660 kg of dried cannabis per year, along with expansion plans to increase production to 1,500 kg/year. A second ACMPR application, also in the readiness stage, is located on Vancouver Island with the potential to eventually produce 900 kg/year.

Earlier this week (http://nnw.fm/35Iml), Choom expanded its portfolio with a Letter of Intent to acquire advanced-stage cannabis production license applicant Flower Power and its wholly owned subsidiary, High Way 10 Cannabis Pharms Inc. Located in Southern Saskatchewan, High Way 10 has a 16,000-square-foot facility that will be capable of producing roughly 1,500 kg of dried cannabis annually. In addition to room for additional expansion, Flower Power is advancing its retail store strategy across the country to create a consumer experience that elevates and evolves the traditional dispensary vibe. It intends to have a hybrid of corporately owned and franchised dispensaries, subject to the formal legalization of recreational cannabis by Health Canada and provincial and municipal guidelines.

Complementary to Choom’s corporate vision, this acquisition marks Choom’s fourth advanced-stage applicant and demonstrates the company’s commitment to scale up its operations to meet the demands of the Canadian recreational market.

Other Players

Hiku Brands (CSE: HIKU) (OTC: DJACF) just received one of four master retail licenses in Manitoba’s highly competitive Request for Proposal process, giving Hiku the right to operate retail cannabis stores in the province (http://nnw.fm/jnd7T). The license, awarded to Hiku’s wholly owned subsidiary, Tokyo Smoke, represents what company CEO Alan Gertner called “a validation of our business model and vision of creating an unsurpassed retail experience for cannabis consumers.”

Through its subsidiaries, Canopy Growth (TSX: WEED) (OTC: TWMJF) is a Canadian licensed producer of medical marijuana operating Tweed Main Street Shops in communities throughout southern Ontario (http://nnw.fm/Er6RT). Tweed Main Street has deep roots in the cannabis community, offering Canada’s most “relied upon brands” under one roof. The company’s medical cannabis orders are sent directly to the client after being processed the same day 99 percent of the time, with an average wait call time of less than two minutes.

Aurora Cannabis (TSX: ACB) (OTCQX: ACBFF) is taking a different retail approach by proposing to create medical cannabis retail outlets by converting existing liquor store retail locations in the province of Alberta (http://nnw.fm/XLeK6). Aurora Cannabis, which cultivates, produces and sells medical cannabis, plans to establish “a new customer experience for adult consumers.” The company recently entered into an agreement to become an online medical cannabis supplier for Shoppers Drug Mart, subject to Health Canada’s approval of an application by Shoppers to be a licensed producer (http://nnw.fm/1o8lW).

ABcann Global (TSX-V: ABCN) (OTCQB: ABCCF) has signed an agreement with Choom to market ABcann’s cannabis products through Choom’s branded retail platform. As part of the deal, ABcann Global is making a strategic $4 million investment into Choom, signaling a strong commitment and belief in the company’s unique, customized approach to the recreational cannabis market (http://nnw.fm/PZto7). As one of the earliest licensed medical marijuana producers in Canada, ABcann has five years of operating experience in the medical marijuana space. The company currently owns and operates a fully functioning 14,500-square-foot facility in Napanee, Ontario, as well as 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

Preparation Counts

Scrambling or playing catch-up is never the best business advice, as any successful entrepreneur will tell you. But being able to use that kind of nimble, quick-thinking, planning-ahead ability should bode well for Canada’s cannabis producers and retailers as summer 2018 looms large on the horizon. Companies are lining up financing, expanding production facilities, designing retail spaces and shoring up supplies to meet the expected demand as Canada begins legalizing recreational cannabis for adults 19 years old and over. As Alexander Graham Bell so famously said, “Before anything else, preparation is the key to success.”

For more information on Choom Holdings, please visit Choom Holdings (CSE: CHOO) (OTCQB: CHOOF).

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

$ETST Expands Presence in Blossoming Hemp-Based CBD Market

March 9, 2018

• Agreement with Mr. Checkout will significantly strengthen the company’s product distribution network
• Human trials launched evaluating CBD-based therapy for opioid addiction
• Application made to uplist to OTCQB in early 2018, attracting more investment

The worldwide cannabidiol (CBD) oil market, which includes products derived from both marijuana and hemp, is projected to grow at a CAGR of more than 39 percent through 2021. The health benefits of CBD oil are the major driver for growth in this market, with global demand steadily on the rise in recent years. Hemp-based CBD oil products in particular are more popular, as they have a lower concentration of psychoactive compound tetrahydrocannabinol (THC) than those derived from marijuana, therefore not requiring a medical prescription (http://cnw.fm/kaL9i). Earth Science Tech, Inc. (OTC: ETST) is one of the companies that is focused on the development of hemp-based CBD products and has taken a number of steps recently to enlarge its presence in this market sector.

Following a revamp of its CBD product line, Earth Science Tech announced on February 13, 2018, that it had concluded an agreement with Mr. Checkout for the distribution of its products via major retailers and stores across the United States. This agreement will strengthen the company’s distribution network, which currently has 10 active representatives targeting distribution to health food stores and clinics. Mr. Checkout is a national group of independent distributors of products to over 60 major retailers and 55,000 stores. It will market ETST’s product line to major retailers such as Walmart, Walgreens and Target.

Earth Science Tech is a biotechnology company focused on the research and development of hemp-based CBD products for the pharmaceutical and nutraceutical industries. It also has a focus on the development of diagnostic tools and medical devices. On February 28, 2018, the company announced that it had finalized plans to conduct human trials on its new CBD-based formulation that targets opioid addiction (http://cnw.fm/rNnQ0). These trials will assess the efficacy of the combination of hemp-based CBD oil with an essential mineral element. Currently, the sole therapy for this condition is a monotherapy based on an essential mineral element. ETST’s formulation is expected to increase the potency and improve the outcome of this therapy.

The company operates through three wholly owned subsidiaries:

• Cannabis Therapeutics, Inc. which develops leading edge, cannabinoid-based products for the pharmaceutical and nutraceutical sectors;
• KannaBidioiD which is focused more on developing products for the recreational use of cannabis, including edibles, vapes and eLiquids;
• Earth Science Pharma, Inc., which develops medical devices and low-cost, noninvasive diagnostic tools, as well as testing processes and vaccines for sexually transmitted diseases.

Cannabis Therapeutics is in the development stage of two CBD-based pharmaceutical drugs and three CBD-based nutraceutical products. These will target a variety of ailments, including depression, anxiety, breast cancer and fatty liver disease. In October 2017, Earth Science Tech announced a collaboration with Clinique SIDA Amité to conduct a mini-trial on its MSN-2 device for the detection of Chlamydia. ETST has also acquired Canna Inno Laboratories Inc., based in Montreal, Canada, which will give the company the opportunity to expand into Canada and gain access to local government grants for pharmaceutical industry innovation.

Earth Science Tech expects to uplist to the OTCQB Venture Exchange in early 2018, which it believes will attract well-funded institutional investors. These recent developments are likely to increase company growth and enlarge Earth Science Tech’s presence in the cannabis industry.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

• Medical Cannabis Payment Solutions’ (REFG) ‘Green’ is the Medical Cannabis Electronic Transaction Solution
• Global Payout, Inc. (GOHE) Financial Solutions Link World Companies of All Sizes
• Marijuana Company of America, Inc. (MCOA) Leading the Way in the Cannabis and Hemp Industry

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$CLWT To Sell Its Stake in Zhejiang Jiahuan Electronics

HONG KONG, March 28, 2018 — Euro Tech Holdings Company Limited (Nasdaq: CLWT) today announced that it has recently signed an Equity Transfer Agreement (the “Agreement”) to sell its 20% equity stake of Zhejiang Jiahuan Electronics Co., Ltd. (“Jia Huan”) to an individual, who is the wife of the holder of the remaining 80% equity stake of Jia Huan, for a purchase price of RMB$31,312,500. The completion of the transaction is subject to completion of all closing formalities, including the need to obtain approval and registration with the relevant governmental authorities and the receipt of payment from the Purchaser. The Company’s decision to enter into the Agreement and dispose of its equity stake in Jia Huan was based upon the intention of Jia Huan’s major shareholder to diversify the business of Jia Huan into new areas that are unrelated to its and the Company’s existing activities.

About Jia Huan

Zhejiang Jia Huan Electronic Co. Ltd. in Zhejiang, China (“Jia Huan”), an established company, has been in business since 1969. 95% of Jia Huan’s business is related to air pollution control and less than 5% is for water and wastewater treatment. Jia Huan designs and manufactures automatic control systems and electric voltage control equipment for electrostatic precipitators which are major air purification equipment for power plants, cement plants and incinerators to remove and collect dust and pollutants from the exhaust stacks. The Company held the 20% equity in Jia Huan since January 2008.

Forward Looking Statements

Certain statements in this news release regarding the Company’s expectations, estimates, present view of circumstances or events, and statements containing words such as estimates, anticipates, intends, or expects, or words of similar import, constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements indicate uncertainty and the Company can give no assurance with regard to actual outcomes. Specific risk factors may include, without limitation, having the Company’s offices and operations situated in Hong Kong and mainland China, doing business in China, competing with Chinese manufactured products, competing with the Company’s own suppliers, dependence on vendors, and lack of long term written agreements with suppliers and customers, development of new products, entering new markets, possible downturns in business conditions, increased competition, loss of significant customers, availability of qualified personnel, negotiating definitive agreements, new marketing efforts and the timely development of resources. See the “Risk Factor” discussions in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F for its fiscal year ended December 31, 2016.

$IVAC oDLC® to Begin Shipping on Top 3 Cellphone Maker’s Flagship Smartphone

Intevac, Inc. (Nasdaq: IVAC), a leading supplier of thin-film processing systems, today formally announced that its market-leading thin-film technology, oDLC^® (optical Diamond-Like-Carbon), is being applied to protect selected decorative back cover glass options for the recently-launched flagship smartphone of a Top 3 Cellphone maker. oDLC is an optically-transparent, protective thin-film coating, which provides significant improvements in the scratch and wear resistance of display cover panels and film coating stacks on the surfaces of all types of mobile electronic devices, as well as point-of-sale and automotive infotainment systems.

Backside cover glass for mobile phones is a recent phenomenon that is addressing a rapidly-growing portion of the high-end smartphone market. While most early adopters of backside cover glass have opted to achieve color variations by coating the inside of the glass, the flagship smartphone launched this week is the first major phone to have decorative back cover glass options where the colors are deposited on the outside of the glass, making them exceptionally vibrant and striking. Intevac’s oDLC protects these decorative coatings from scratches and wear arising out of daily use.

Truly Opto-electronics (Shanwei City, China), a major supplier of cover glass and touch panel technologies to mobile electronics manufacturers and owner of multiple INTEVAC VERTEX^® systems, went through an intensive testing process lasting several months to ensure that oDLC met the stringent specifications laid out by the technical team at the Top 3 Cellphone maker.

“Truly Opto-electronics’ Engineering team thoroughly qualified Intevac’s oDLC protective coating technology with the decorative coating on the backside glass that went into this flagship smartphone from a Top 3 Cellphone maker. This production order is a significant validation of our coating capabilities meeting top-tier customer requirements,” commented Mr. Li, Managing Director of Truly Opto-electronics. “We believe that oDLC offers superior film protection at a low cost to customers. We are working with other customers on positioning oDLC for several different production applications.”

“Intevac is excited about our strong partnership with Truly, which has led to the adoption of oDLC by a leading cellphone maker on their flagship smartphone, and we look forward to leveraging this design win to drive adoption of oDLC at multiple mobile phone customers across a range of applications,” added Jay Cho, Executive Vice President and General Manager of Intevac’s Thin-Film Equipment business.

The thin-film equipment that enables the oDLC solution is the INTEVAC VERTEX multi-stage physical vapor deposition (PVD) system. The VERTEX PVD system deposits the oDLC thin-film coating vertically and at the low process temperatures required for display cover panel processing. The VERTEX is an optimal production solution for small individualized substrates, achieving the highest level of throughput at the lowest possible cost.

About Intevac

Intevac was founded in 1991 and has two businesses: Thin-film Equipment and Photonics.

In our Thin-film Equipment business, we are a leader in the design and development of high-productivity, thin-film processing systems. Our production-proven platforms are designed for high-volume manufacturing of substrates with precise thin film properties, such as the hard drive media, display cover panel, and solar photovoltaic markets we serve currently.

In our Photonics business, we are a recognized leading developer of advanced high-sensitivity digital sensors, cameras and systems that primarily serve the defense industry. We are the provider of integrated digital imaging systems for most U.S. military night vision programs.

For more information call 408-986-9888, or visit the Company’s website at www.intevac.com.

$NAUH Schedules Fiscal 2018 Financial Results Release

RAPID CITY, S.D., March 28, 2018 — National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University, a regionally accredited, proprietary, multi-location institution of higher learning, today announced that it intends to release financial results for its fiscal 2018 third quarter and nine months ended February 28, 2018, after the closing of the stock market on Wednesday, April 4, 2018. The Company will then discuss those results in a conference call on Thursday, April 5, 2018, at 11:00 a.m. ET.

The dial-in numbers are:
(877) 407-9078 (U.S.)
(201) 493-6745 (International)

Accompanying Slide Presentation and Webcast
The Company will have an accompanying slide presentation available in PDF format at the “Investor Relations” section of the NAU website at www.national.edu. The presentation will be made available 30 minutes prior to the conference call.  In addition, the call will be simultaneously webcast over the Internet via the “Investor Relations” section of the NAU website or by clicking on the conference call link: http://national.equisolvewebcast.com/q3-2018. The webcast will be archived and accessible for approximately 30 days.

About National American University Holdings, Inc.
National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-location institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first location in Rapid City, South Dakota, and has since grown to multiple locations in several U.S. states. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.

$ETST Sees Explosive Sales Growth in 2018

March 28, 2018

• Nickolas Tabraue, ETST president, gives up COO position to Gagan Hunter, noting that the move completes the ‘puzzle’ to drive company to new heights in alternative medicine market
• Biotech company is focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing high-grade, industrial hemp cannabidiol (CBD)
• Company projects a breakout year in 2018, in part due to revamping of its executive team and introducing a new marketing strategy for its repositioned and repackaged line of industrial hemp products

Earth Science Tech, Inc. (OTC: ETST), by naming Gagan Hunter as its new COO, has completed a transition, positioning the company to reach ‘new heights’ with a new team in place and a revamped marketing strategy for its industrial hemp-sourced line as a cannabinoid complex, as detailed by Nickolas Tabraue, company director and president, in a recent news release (http://cnw.fm/i0XFy). Tabraue, who served as COO prior to the appointment of Hunter, said that ETST has positioned itself for ‘explosive sales growth’ in 2018 (http://cnw.fm/JxpO7).

Hunter said that he looks forward to strengthening the company’s operations. He has 20 years of experience in the natural products industry, joining a number of seasoned additions to the ETST team. Earlier, the company put in place the team of Jill Buzan as chief sales officer, Sergio Castillo as chief marketing officer, and Gabriel Aviles as chief learning officer (http://cnw.fm/2vgQE).

Tabraue added, “I feel that we finally have the last piece of our puzzle in place to take ETST to new heights. Gagan has many great ideas to implement that will help the company work more efficiently and with greater organization. We now have every major role managed by passionate, likeminded individuals to truly make ETST an innovative, trusted brand in the alternative medicine space.”

Earth Science Tech is an innovative biotech company based in Doral, Florida. It markets a repositioned and repackaged line of High Grade Full Spectrum cannabidiol (CBD) oil products.  Focused on manufacturing and marketing cannabinoid products to the pharmaceutical and nutraceutical markets, it also conducts R&D for low-cost, non-invasive medical devices.

The company holds three wholly owned subsidiaries, including:

• Earth Science Pharmaceutical, which develops medical diagnostic tools and vaccines;
• Cannabis Therapeutics, an emerging biotechnology company; and
• KannaBidioiD, which is focused on cannabidiol production and distribution in the recreational space.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

• Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Building Seasoned Leadership Team for Growing Cannabis Portfolio
• The Tinley Beverage Company Inc. (CSE: TNY) (OTCQX: TNYBF) Brings Healthy Hemp and Cannabis Drinks to Market
• Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Named to the CSE25 Index

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net